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9General introduction 1
Scope of this thesis
This thesis aims to provide insight in a specific approach of screening for type 2 
diabetes: opportunistic targeted screening in primary care. This method entails 
screening in asymptomatic individuals at high risk for undiagnosed type 2 
diabetes during regular healthcare consultations. This approach is particularly 
attractive in general practice, where information is available of individuals’ 
medical and family history, and other personal circumstances to identify risk 
status. There are strong indications that integrating screening and prevention in 
regular (primary) healthcare is effective and efficient. In the study reported in this 
thesis – the Diabscreen study – the information to assess risk for type 2 diabetes 
was drawn from the general practitioner’s (GP) electronic medical record (EMR). 
Risk information is already available in an EMR, and may be more accurate and 
complete compared to data obtained from a questionnaire. And with continuity of 
care in general practice, the GP’s EMR might be an attractive, inviting tool for a 
systematic and repeated identification of high-risk patients in opportunistic 
screening. 
 In this chapter, type 2 diabetes and the key issues of screening for type 2 diabetes 
are introduced. Subsequently, the main screening approaches are described, and 
the Diabscreen study is briefly explained. Finally, the objectives of this thesis are 
listed, followed by an outline of the chapters.
Type 2 diabetes
Diabetes mellitus is a metabolic disorder primarily defined by chronic hyperglycemia, 
giving rise to risk of microvascular complications (diabetic retinopathy, nephropathy 
and neuropathy). It is also associated with reduced life expectancy, mainly due to 
an increased risk of macrovascular complications (cardiovascular disease [CVD], 
for example ischemic heart disease, stroke and peripheral arterial disease), and 
with diminished quality of life.1,2
 The classification of diabetes is based on etiological types. In 90% of the cases, 
patients have type 2 diabetes. This type results from a progressive insulin secretory 
defect in the pancreas’ beta-cells on the background of insulin resistance.3 Type 2 
diabetes is characterized by a long preclinical (asymptomatic) period of up to 12 years,4 
and one third to one half of all people with type 2 diabetes may remain undiagnosed 
all these years.5-7 By the time of clinical diagnosis, when patients present with 
signs or symptoms of hyperglycemia (eg, polyuria and polydipsia), many already 
have developed complications.4,8-10 The prevalence of type 2 diabetes is rising 
globally, mainly due to ageing and an increase of overweight and obese people. 
10
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The number of adults with type 2 diabetes is expected to double in the next 
decades, which will dramatically increase the burden of disease and healthcare 
costs.11-13
Screening for type 2 diabetes
Glycemic control and cardiovascular risk management (mainly treatment of 
hypertension and hypercholesterolemia) have been proven to decrease micro -
vascular and macrovascular disease and mortality in patients with clinically 
diagnosed type 2 diabetes.14-16  And there is some evidence that lifestyle and pharma-
cotherapeutic interventions can prevent or slow the progression from prediabetes 
– impaired fasting glucose and impaired glucose tolerance – to diabetes and reduce 
the risk of CVD.14,15 
 Type 2 diabetes appears to meet the suitability criteria (or principles) for 
screening, determined by Wilson and Jungner for the World Health Organization 
in 1968 (Table 1): the disease is an important health problem (item 1); depending 
on access to healthcare, type 2 diabetes can be easily diagnosed and treated, and 
treatment seems effective (items 2, 3 and 8); its natural history is well understood, 
with a long preclinical stage during which it can be detected (items 4 and 7); 
suitable screening tests exist and the psychological impact on patients of screening 
appears to be limited (items 5 and 6); health economic models have shown that 
certain screening strategies can be cost-effective (item 9); and, especially in primary 
healthcare settings, testing for diabetes can be repeated easily (item 10).14,17-24 
At present, however, no direct evidence is available from long-term studies, in 
particular randomized controlled trials (RCTs), to show that treatment of patients 
with type 2 diabetes detected through screening results in lower vascular event 
rates when compared with treatment of patients diagnosed by clinical signs or 
symptoms.14,15 In addition, it is unclear whether the economic cost of screening can 
be justified. And there is no consensus on which screening test to use, which 
diagnostic cut-off points are best, and what the optimal screening interval is.18,19 
 These considerations notwithstanding, screening for diabetes is encouraged 
nowadays. But without evidence of a direct benefit of routine population-based 
screening for type 2 diabetes, it is urged to target individuals at high (vascular) 
risk.19,20,25 This includes (1) high risk of undiagnosed type 2 diabetes, for example 
persons with obesity or a family history of diabetes, or people from a high-risk 
ethnical group; (2) high risk for CVD, for example patients with hypertension or 
hypercholesterolemia; (3) established CVD, for appropriate disease management. 
Screening costs will be lower with targeted screening, whereas there is a relatively 
11
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clear potential health benefit. While most clinical guidelines now recommend 
screening for type 2 diabetes in high-risk groups,26-29 there is, however, no standardized 
screening approach. 
Screening approaches
There are basically two main approaches to screen for type 2 diabetes: population-
based screening or opportunistic screening.17,18,24,30,31 Both population-based and 
opportunistic screening can be performed in a subgroup of high-risk persons 
(targeted or selective screening).31 Occasionally, individuals may be invited to be 
screened in a public place, for example in a supermarket, also called haphazard 
screening, but with a low diabetes prevalence and no support for follow-up, this is 
both inefficient and inadequate.30 This also applies to the wide variety of glucose 
tests that are offered online nowadays.24 
Population-based screening
Population-based screening was originally directed at an entire population, 
offering blood glucose testing to every (adult) individual (known as ‘universal 
screening’). Earlier epidemiological studies have used this design to assess diabetes 
prevalence,5,32 and so have early clinical screening studies.33 But due to a low 
prevalence of diabetes in most populations, universal screening is usually costly 
and inefficient. 
Table 1  Principles of early disease detection by Wilson and Jungner (1968)17
1. The condition sought should be an important health problem;
2. There should be an accepted treatment for patients with recognized disease;
3. Facilities for diagnosis and treatment should be available;
4. There should be a latent or early symptomatic stage;
5. There should be a suitable test or examination;
6. The test should be acceptable to the population;
7. The natural history of the condition, including development from latent to declared 
disease, should be adequately understood;
8. There should be an agreed policy on who to treat as patients;
9. The cost of case finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical care  
as a whole;
10. Case finding should be a continuing process and not a ‘once and for all’ project.
12
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 Recent population-based screening programmes have used a stepwise approach 
to target high-risk individuals. They were identified by means of a questionnaire 
or simple risk score that was sent to the patient’s home, followed by an invitation 
for blood glucose testing.34,35 In another study, GPs selected all overweight or obese 
patients older than 50 years using the EMR, and invited them to screening clinics.36 
Population-based screening has the advantage that it is mathematically precise, 
readily reproducible, and can operate largely independent of the clinicians’ skills.31 
But selecting and inviting participants may also be expensive, time-consuming 
and have a low yield.18,37
Opportunistic (targeted) screening
Opportunistic screening is a form of case finding which involves screening 
individuals during routine healthcare encounters, usually primary care visits.18,30,31,38,39 
In opportunistic screening it is the patient who makes the appointment, for a 
reason other than the condition for which screening is offered. This approach is 
different from screening programmes in which the invitation to come forward 
and be screened is part of the programme.30 Opportunistic screening has several 
advantages. It is not expensive because it requires fewer resources to conduct 
screening tests and to perform follow-ups, and when performed in a familiar 
healthcare setting it gives high acceptance rates and repeated opportunities to 
screen. A primary care setting has also the risk factor information needed for 
targeted screening. On the other hand, it may have poor coverage since it depends 
on the patients consulting for some reason, and on the clinical alertness of the 
doctors or practice nurses. Sometimes it may be inappropriate to offer screening 
during a consultation. And there is a tendency that some people get too many tests 
too often, whereas others get too few tests too infrequently.18,31 Earlier, opportunistic 
screening in general practice using a screening questionnaire to target high-risk 
groups was feasible and had a high participation rate.40 Opportunistic targeted 
screening using clinical risk factor information from the EMR may be a more 
efficient and continuous method of detecting undiagnosed type 2 diabetes during 
usual primary healthcare. This screening approach has been investigated in the 
Diabscreen study. 
The Diabscreen study
The Diabscreen study was an opportunistic targeted screening programme 
embedded in daily routine care in general practices in the Netherlands, and 
consisted of a stepwise screening procedure: (1) identification of high-risk and 
low-risk individuals using the EMR; (2) one and if indicated a second capillary 
13
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fasting plasma glucose (FPG) measurement; and (3) if indicated, a venous FPG. 
Using a computerized cross-sectional analysis of diabetes risk factor information 
for each patient from the practices’ EMR, the patient’s risk for undiagnosed 
diabetes (high or low risk) was marked in the EMR. 
 During a usual care consultation in the following year, the EMR reminded the 
GP to verify and, in the case of missing data, complete the patients’ risk profile and 
to invite high-risk patients for an FPG measurement. The study setup and results 
are described in detail in Chapters 2, 3 and 4.
The partner’s perspective
Not just the patient but also family members, in particular the partner, play an 
important role in type 2 diabetes.41,42 As in other chronic diseases, in type 2 
diabetes self-management is essential.43 Patients need to exercise and follow a diet, 
have to take medications and sometimes require insulin injections.26,27,29,44 These 
self-care behaviours are influenced by both patients’ and partners’ beliefs – 
so-called illness perceptions – regarding type 2 diabetes, which are associated 
with health outcomes.45,46 In diabetes education and treatment, interventions that 
target differences in illness perceptions between patients and their partners have 
been advocated.47 
 Although the psychological impact of a screening-based diagnosis of type 2 
diabetes on patients is generally limited,21 the route to diagnosis of diabetes – by 
screening in asymptomatic individuals or by clinical signs or symptoms –  may 
affect the illness perceptions of patients and their partners. It may thus be an 
important factor to consider in diabetes education programmes. 
Long-term effectiveness of screening
The effectiveness of screening for type 2 diabetes and early treatment after 
diagnosis should preferably be estimated by an RCT. Such a trial should contain a 
control group of individuals who meet the criteria for screening but who do not 
receive it, thus truly comparing ‘screened’ with ‘not screened’ patients. This 
however appears to be both unethical and unachievable in clinical practice, so at 
present, no direct supportive evidence for the effectiveness of screening exists.14,15 
Alternatively, an observational study may be used to assess whether treatment of 
patients with type 2 diabetes detected through screening results in lower vascular 
event rates when compared with treatment of patients diagnosed by clinical signs 
or symptoms. Such an approach may be feasible and acceptable in general practice.
14
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Objectives
The first objective of this thesis was to evaluate the feasibility and yield of 
opportunistic targeted screening in primary care. 
 Secondly, to address the partner’s perspective of screening, this thesis aimed 
to investigate how the route to diagnosis of type 2 diabetes – through screening or 
by clinical signs or symptoms – affects illness perceptions in families, particularly 
in patients and their partners. 
 The third objective was to assess the effectiveness on long-term vascular outcomes 
of opportunistic targeted screening for type 2 diabetes, compared with a clinical 
diagnosis.
Outline of this thesis
Chapters 2, 3, 4 and 5 are about the feasibility and yield of opportunistic targeted 
screening. In Chapter 2 the value of the GP’s EMR in identifying patients at risk for 
undiagnosed type 2 diabetes and the feasibility to use this information in usual 
care to initiate screening are assessed. In Chapter 3 the stepwise protocol of 
opportunistic targeted screening is evaluated. In Chapter 4 the yield of opportunistic 
targeted screening is assessed and the diagnostic value of various risk factors is 
investigated. And Chapter 5 contains a comment on a modelling study which 
investigated the cost-effectiveness of screening for type 2 diabetes.
 Chapter 6 focuses on the partner’s perspective of screening. In this chapter 
data from screen-detected type 2 diabetes patients and their partners are compared 
with data from patients and their partners after a clinical diagnosis.
 Chapters 7 and 8 are about the long-term effectiveness of screening. In Chapter 
7 it is assessed whether opportunistic targeted screening results in lower long-term 
vascular event rates compared with diagnosis on the basis of clinical signs or symptoms. 
Chapter 8 contains the response to a comment on the publication presented in the 
previous chapter. 
 And finally, in Chapter 9, the main findings of this thesis are summarized and 
reflected on. The main methodological issues of the studies and the ongoing screening 
debate are discussed. The chapter ends with clinical implications, recommendations 
for future research, and five key messages.
15
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Abstract
Background Screening for type 2 diabetes is recommended in at-risk patients. The 
general practitioner’s (GP) electronic medical record (EMR) might be an attractive 
tool for identifying them.
Objective To assess the value of the GP’s EMR in identifying patients at risk for 
undiagnosed type 2 diabetes and the feasibility to use this information in usual 
care to initiate screening.
Methods In 11 Dutch general practices (25 GPs), we performed an EMR-derived 
risk assessment in all patients aged 45 to 75 years, without known diabetes, 
identifying those at risk according to the American Diabetes Association recommen-
dations. Patients with an EMR-derived risk or risk after additional risk assessment 
during regular consultation were invited for capillary fasting plasma glucose (FPG) 
measurement.
Results Of 13,581 patients, 3,858 (28%) had an EMR-based risk (hypertension, 
cardiovascular disease, lipid metabolism disorders and/or obesity). Additional risk 
assessment in those without an EMR-based risk showed that in 51%, greater than 
one risk factor was present, mainly family history (51.2%) and obesity (59%). Ninety 
per cent returned for the FPG measurement. In both groups, we found patients 
with an FPG exceeding the cut point for diabetes (5.9% versus 4.1%). 
Conclusions With additional risk assessment during consultation, the GP’s EMR 
was valuable in identifying patients at risk for undiagnosed type 2 diabetes. It was 
feasible to use this information to initiate screening. At-risk patients were willing 
to take part in screening. Better registration of family history and obesity will 
improve the EMR as a tool for identifying at-risk patients in opportunistic screening 
in general practice. 
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Introduction
Main reason to urge for screening for type 2 diabetes mellitus is the long preclinical 
period of diabetes. One-third to half of all people with diabetes remain undiagnosed 
for many years. In the meantime, complications already begin to develop.1 Starting 
treating patients with type 2 diabetes at an earlier stage might prevent or delay the 
development of complications.2 However, at this moment, no evidence is available 
for the effectiveness of screening programmes in reducing diabetes-related morbidity 
and mortality. There is also little knowledge about the ethical, psychological, and 
social consequences of both true and false screening results, and there is no 
consensus on the applied screening test and diagnostic cut off points.3,4 
 Notwithstanding these considerations, nowadays screening for type 2 diabetes 
is encouraged. It is recommended to perform screening in a subgroup of patients 
at risk for undiagnosed type 2 diabetes.5-8 As screening should also be a systematic 
and continuous process,3 opportunistic screening of such at-risk patients might be 
an interesting screening method in general practice. This involves screening of 
at-risk individuals during usual care, who are seen by health care professionals for 
reasons not related to the condition for which screening is offered.9 At-risk patients 
can be identified using questionnaires or risk scores.10-12 A pragmatic approach 
might be assessing risk using risk factors for undiagnosed type 2 diabetes that are 
already registered in the medical records of the general practitioner (GP).
 Relevant medical informations like diagnoses, medication use and referrals are 
available in the GP’s medical record system, nowadays often computerized. If GPs 
are well trained and software is user-friendly, an electronic medical record (EMR) 
can be accurate and complete.13 The GP’s EMR might therefore be an attractive, 
inviting tool for identifying at-risk patients in opportunistic screening.
 The aim of this study was to assess the value of the GP’s EMR in identifying people 
at risk for undiagnosed type 2 diabetes and the feasibility to use this information 
in usual care to initiate screening.
Methods
Patients and setting
Patients were recruited from 11 general practices (25 GPs) in the Netherlands: 
seven of these practices were participating in the Academic Research Network of 
the Department of General Practice of the Radboud University Nijmegen Medical 
Centre, CMR/NMP,14 two in the Registration Network Family Practices of the 
University Maastricht (RNH)15 and two practices were related to the network of the 
VU University Medical Center Amsterdam.16 All patients aged ≥45 and ≤75 years 
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and not known with type 2 diabetes who were listed with these practices were 
considered for the study. Diabetes – both known and undiagnosed – was defined as 
having a fasting plasma glucose (FPG) ≥7.0 mmol/l on two different days in 
asymptomatic patients or a single random plasma glucose >11.0 mmol/l in patients 
with diabetes related symptoms. Impaired fasting glucose (IFG) was classified as 
having a single FPG value ≥6.0 mmol/l and <7.0 mmol/l.17,18
 All practices used the Promedico EMR software (Promedico ICT Inc., Nieuwegein, 
the Netherlands). Registration of diagnoses was based on the electronic version of 
the International Classification of Primary Care (ICPC codes).19 Prescribed 
medication was coded according to the Anatomical Therapeutic Chemical 
classification system (ATC codes).20 This study is part of an opportunistic screening 
programme for type 2 diabetes in general practice – the Diabscreen study.
Methods
People were considered to be at risk for undiagnosed type 2 diabetes when having 
one or more of the following diabetes risk factors, derived from the American 
Diabetes Association’s (ADA) recommendations in screening for type 2 diabetes: a 
family history of diabetes (parent and/or brother and/or sister with diabetes), 
hypertension, cardiovascular disease (myocardial infarction, heart failure, atrial 
fibrillation, stroke, peripheral vascular disease), lipid metabolism disorders, 
obesity (body mass index [BMI] >27), and a history of gestational diabetes mellitus 
(GDM).6 We translated these risk factors into a set of matching ICPC and ATC codes 
(Table 1). 
Family history of diabetes and a history of GDM were not consistently coded in the 
EMR by the GPs and could therefore not be used in this list. At the time of study, 
no medication was registered to treat obesity and therefore an ATC code was not 
yet available. Almost all patients were Caucasian, so ethnicity was in this study not 
used as a risk factor. Having children with a birth weight more than 4,000 g was 
left out as it was not registered. An EMR-derived risk assessment was conducted to 
identify the patients with ICPC and/or ATC codes mentioned in Table 1. For this 
purpose, we had developed software that enabled us to extract ICPC and ATC 
information of each patient from the practices’ EMR and to analyse these data 
anonymously at the university department.
When ATC but no ICPC codes for cardiovascular disease and hypertension were 
present, the patients’ own GPs were asked to check clinical information in the 
EMR. In case medication matching these codes had been prescribed for other 
conditions than cardiovascular disease or hypertension, this was considered not a 
diabetes risk factor.
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The EMR-derived risk status (risk/no risk) was then marked in the EMR with an 
alert to trigger GPs when patients visited the practice for usual care during the 
following year. GPs were asked to initiate FPG measurement in at-risk patients. For 
patients without risk factors, the GPs needed to verify the EMR risk profile by 
checking and in case of missing data completing risk factors coded in the EMR 
(hypertension, cardiovascular disease, lipid metabolism disorders and obesity) and 
checking risk factors not coded in the EMR (family history of diabetes and a history 
of GDM). In case this additional risk assessment revealed risk, the patient was 
invited by the GP for FPG measurement similar to patients with an EMR-derived 
risk. FPG measurement was conducted in the patients’ own general practice by 
their own practice assistant. In all participating practices, a Gluco Touch® (LifeScan 
Beerse [Belgium; LifeScan Benelux]) plasma calibrated capillary blood glucose 
meter was used. Prior to the start of the study, all meters were checked and 
adjusted if necessary by its manufacturer. 
 The practice assistants were trained in using the meters. Patients with a screening 
FPG >6.0 mmol/l (the cut point for IFG as earlier defined) were followed up for 
Table 1  Selection codes matching diabetes risk factors
Diagnoses (ICPC codes) Medication (ATC codes)
Hypertension Elevated blood pressure (K85)
Hypertension, complicated (K86)
Hypertension, uncomplicated (K87)
Diuretics (C03)
Beta blockers (C07)
Calcium channel blockers (C08)
Angiotensin-converting enzyme 
inhibitors (C09)
Angiotensin II receptor blockers 
(C09)
Cardiovascular 
disease
Ischaemic heart disease with  
angina (K74)
Acute myocardial infarction (K75)
Ischaemic heart disease without angina 
(K76)
Heart failure (K77)
Atrial fibrillation/flutter (K78)
Transient cerebral ischaemia (K89)
Stroke/cerebrovascular accident (K90)
Cerebrovascular disease (K91)
Atherosclerosis/peripheral  
vascular disease (K92)
Anticoagulants (B01)
Platelet aggregation  
inhibitors (B01)
Cardiac glycosides (C01)
Antiarrhythmics (C01)
Nitrates (C01)
Lipid metabolism 
disorders
Lipid disorder (T93) Serum lipid reducing agents 
(C10)
Obesity Obesity (BMI >30 kg/m2) (T82)
Overweight (BMI 27-30 kg/m2) (T83)
NA
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further diagnostic testing according to the earlier described definition. The two-step 
screening strategy we used is topic of a separate publication.
Statistical tests
Statistical analysis was performed using the chi-square test for categorical data 
and the Student’s t-test or Kruskal-Wallis test for means where appropriate. Data 
were analysed by means of the SAS 8.0 software package.
Results
In the 11 participating practices, 49,229 patients were registered, of whom 14,457 
were aged ≥45 and ≤75 years. In 876 (6%) patients, diabetes mellitus had already 
been diagnosed, leaving 13,581 patients for the study (Figure 1). EMR-derived risk 
assessment identified 3,858 (28%) at-risk patients leaving 9,723 (72%) patients 
without an EMR-derived risk. Characteristics of patients with and without an 
EMR-derived risk and patients already diagnosed with diabetes are shown in Table 2. 
No significant difference in sex was found between the three groups. Patients with 
known diabetes were older than patients with an EMR-derived risk (mean age 61.4 
versus 60.5 years), who in turn were older than those without an EMR-derived risk 
(mean age 60.5 versus 55.2 years). Younger patients were less likely to be at risk 
than older patients. We found little interpractice variation. For example, Table 2 
shows little interpractice variation concerning mean age.
Table 2   Baseline characteristics of the study subgroups and known diabetes mellitus
EMR-derived 
risk
n = 3,858
No EMR-
derived risk
n = 9,723
Known 
diabetes 
mellitus
n = 876 P
Sex (% male) 48.6 49.3 49.2 NS
Mean age, years (95% CI) 60.5 (60.2-60.8) 55.2 (55.0-55.3) 61.4 (60.9-61.9) <0.0001
Interpractice variation in 
mean age (years)
57-63 52-57 57-64 –
45-55 years (%) 17.1 79.7 3.2 <0.0001
55-65 years (%) 31.3 61.0 7.7
65-75 years (%) 44.0 45.2 10.8
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EMR-derived risk 
In the course of 1 year, the GPs succeeded in bringing up and discussing screening 
during consultation in 2,270 (59%) of the patients with an EMR-derived risk (Figure 1). 
Of them, 2,081 (92%) could be included for the study (reasons for exclusion 
mentioned in Figure 1). We found a risk factor prevalence of 42.4% for hypertension, 
25.6% for cardiovascular disease, 16.5% for lipid metabolism disorders and 30.0% 
for obesity. All 2,081 patients were invited for FPG measurement.
At risk after additional risk assessment 
In 3,363 (35%) of the patients without an EMR-derived risk, screening was discussed 
during consultation (Figure 1). Of them, 3,196 (95%) could be included for the 
study. Additional risk assessment showed that in 1,643 (51%) at least one risk factor 
for diabetes was present. In particular, family history of diabetes and obesity were 
found as a source of missing data: the prevalence after checking was 51.2% (family 
history), 59.0% (obesity) and 1.0% (history of GDM). All 1,643 patients at risk after 
additional risk assessment were then invited for an FPG measurement. 
FPG measurement 
In total, 1,886 patients with an EMR-derived risk (91%) and 1,449 patients at risk 
after additional risk assessment (88%) returned for an FPG measurement. See 
Figure 1 and Table 3. Patients of the first group were more often male (44.2% versus 
39.9%) and older (mean age 60.3 versus 55.6 years) than patients of the latter group. 
In both groups, we found patients with an FPG exceeding the cut point for IFG 
Table 3   Sex, mean age and mean FPG and percentage of patients with FPG values 
exceeding IFG or diabetes cut points (bold printed border in Figure 1)
EMR-derived risk and 
FPG measured
n = 1,886
At risk after additional 
risk assessment and 
FPG measured 
n = 1,449 P
Sex (% male) 44.2 39.9 <0.05
Mean age, years (95% CI) 60.3 (59.9-60.6) 55.6 (55.2-56.0) <0.0001
Mean FPG, mmol/l (95% CI) 5.6 (5.5-5.6) 5.4 (5.4-5.5) <0.001
FPG 6.1-7.0 mmol/l (%) 13.5 9.6 –
FPG ≥7.0 mmol/l (%) 5.9 4.1 –
FPG = fasting plasma glucose; IFG = impaired fasting glucose.
29
Identifying people at risk for undiagnosed type 2 diabetes
2
(13.5% versus 9.6%) and diabetes (5.9% versus 4.1%). Patients with an EMR-derived 
risk had a slightly higher mean FPG (5.6 versus 5.4 mmol/l).
Discussion
Summary of main findings
Identifying people at risk for undiagnosed type 2 diabetes mellitus using the 
medical data stored in the GP’s EMR could be achieved during daily routine 
practice, without any further support, e.g. from trial nurses. Of the population 
aged ≥45 and ≤75 years and not known with diabetes, 28% had an EMR-derived 
risk. Of the remaining 72% without an EMR-derived risk, 51% were also found to be 
at risk after additional risk assessment during usual care. So, in total, about 65% of 
the study population were at risk.
 The diabetes risk factors hypertension, cardiovascular disease and lipid metabolism 
disorders were well registered in the EMR and could easily be retrieved. Hyper - 
tension and cardiovascular disease accounted for 62% of the number at risk. In 
particular obesity and a family history of diabetes were poorly registered, and 
were mainly retrieved with additional risk assessment during consultation. 
Although patients had to return in a fasting state for the FPG measurement, they 
were highly willing to do so. Ninety per cent of patients who were invited returned 
for the measurement. 
 In both risk groups (EMR-derived and additional risk assessment) we found 
patients with an FPG value exceeding the cut point of both IFG and diabetes 
mellitus. Their mean FPG values were about equal. So, EMR-derived and additional 
risk assessment followed by screening in at-risk patients from both groups seems 
worthwhile. 
Strengths and limitations of the study
As mentioned earlier, screening should be performed systematically and continuously. 
This important condition can be fulfilled if one uses the GP’s EMR combined with 
an EMR generated alert, as applied in our study. In order to include possible new 
at-risk patients, identification and labelling of people at risk for undiagnosed type 
2 diabetes should be repeated by running the EMR risk extraction software, for 
example every 3 years.
 In 1 year, the GP succeeded in bringing up and discussing screening during 
consultation in about 60% of patients with an EMR-derived risk, and in 35% of those 
without an EMR-derived risk. As this screening method could be used continuously, 
it is estimated that within a period of 3 years, all patients, especially those at risk, 
would have visited their GP. This equals the 3-year interval recommended by the 
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ADA in screening for type 2 diabetes. The higher enrolment of patients for 
screening from the group identified by the EMR might be caused by the fact that, 
especially in the beginning of the study, GPs were focused on screening within 
patients with risk factors registered in the EMR. It may also indicate the user-
friendliness of such approach. Their risk was clear and discussing screening took 
less time than additional risk assessment as was done in the second group. 
Furthermore, the fact that one or more risk factors were recorded in the EMR 
reflected that co-morbidity was present. Such patients usually visit the GP more 
often, increasing the possibility to discuss the need for screening. 
 All participating general practices were related to a university department of 
general practice, which might have positively influenced adherence to protocol. 
Nevertheless, they were all standard community practices with a population 
representative of the Dutch population and a diabetes prevalence equal to that in 
the Netherlands.14-16,21 And although we found that some GPs recruited better than 
others, overall we found little interpractice variation. The fact that the Dutch 
system of primary care provides for universal access and continuity of patient 
registration enabled us to use the GP’s EMR in a continuous screening programme. 
In countries with a different health care system, our screening approach might 
therefore be less feasible. 
 Cross-checking of medication information by the patients’ GPs was necessary 
to improve validation, but was time consuming. When clinical information (ICPC) 
in the future is more complete, this would not be necessary anymore, as risk then 
can be reliably assessed merely on the basis of clinical information. 
 To screen for type 2 diabetes, we used the FPG test rather than the oral glucose 
tolerance test (OGTT). The OGTT consists of an FPG and 2-hour plasma glucose 
value and has been considered as the gold standard test in diagnosing diabetes. 
The FPG test is nevertheless recommended for screening in clinical settings as it is 
easier and faster to perform, more convenient and acceptable to patients and less 
expensive.6,22
 The portable glucose meters we used are user-friendly and readily available in 
general practice. A potential set back is their variability,23 and consequent risk of 
false-positive and false-negative outcomes. This study was directed at the analysis 
of identification of at-risk patients and reviewed a single testing. The two-step 
approach, in which patients with glucose levels above the threshold were measured 
again, did address the problems of false positives. To take care of false-negative 
results, the procedure must be repeated – something that is beyond the scope of 
this paper, but feasible in daily care.
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Comparison with existing literature
In literature, several methods for identifying at-risk patients have been described. 
Smith et al.24 described an opportunistic diabetes screening study performed in 
general practice using a questionnaire presented to patients while waiting to see 
their doctor. Participation rate was also high (93%) and 43% had at least two risk 
factors. If performed continuously or repeated regularly, such a method might 
help improving quality of the EMR in a continuous screening programme. 
 Greaves et al.25 showed that identifying patients with type 2 diabetes and IFG 
using data stored in the GP’s databases was feasible. Screening of patients with a 
BMI ≥27 and aged >50 by fasting glucose identified a substantial prevalence of 
undetected type 2 diabetes and IFG. But instead of an opportunistic approach, they 
invited at-risk patients to screening clinics run by trained practice nurses, and 
other risk factors like family history of diabetes or hypertension were not 
considered. Nevertheless, the simple screening system they describe – like ours – 
would promote an efficient use of scarce primary care resources especially when 
part of a broader cardiovascular disease reducing screening programme. 
 Other studies concerning screening for type 2 diabetes mainly used questionnaires 
or risk scores to identify at-risk patients, instead of data already present in the 
EMR.10-12
Implications for clinical practice and future research
Although it was feasible to use the EMR in diabetes screening, it was not valuable 
without additional risk assessment and updating risk information during 
consultation. Jordan et al.26 concluded in a recent systematic review concerning 
morbidity coding in the GP’s EMR that a high quality of coding can be achieved, 
although it is not yet clear which methods can encourage and help GPs to improve 
quality of coding. 
 Our study showed that 65% of the population consulting the GP were at risk 
when applying the current ADA recommendations. About the same figure (70%) 
was found in the US National Health and Nutrition Examination Survey.1 Although 
high percentages, we would not recommend screening all middle-aged people, for 
example, considering the possible consequences of falsely positive test results, the 
burden of invasive blood testing and costs of screening tests. Our figures showed 
that 62% of those at risk have either hypertension or cardiovascular disease. The 
US Preventive Services Task Force recommendations stress that patients at 
increased risk for cardiovascular disease may benefit most from screening for type 
2 diabetes. Diabetes screening should be part of an integrated approach to reduce 
cardiovascular risk.5-8 If FPG measuring would be a structural part of care in all 
patients with cardiovascular morbidity and hypertension, the number of at-risk 
patients to be screened would be considerably reduced. This emphasizes the 
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importance of a systematic registration of overweight/obesity and family history 
of diabetes in primary care databases. 
Conclusion
The GP’s EMR is an attractive tool for identifying at-risk patients to initiate screening 
during usual care. With additional risk assessment during consultation, the GP’s 
EMR was valuable in identifying patients at risk for undiagnosed type 2 diabetes. 
It was feasible to use this information to initiate opportunistic screening. Patients 
found to be at risk were highly willing to take part in screening. 
 Better registration of family history of diabetes and obesity will improve the 
EMR as a tool for identifying at-risk patients in opportunistic screening in general 
practice. 
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Abstract
Aim To evaluate a stepwise protocol in opportunistic screening for type 2 diabetes.
Methods From 2000 to 2001, in 11 Dutch general practices (n = 49,229) we invited 
at-risk patients during usual care for a capillary fasting plasma glucose (cFPG1) 
measurement. If >6.0 mmol/l, a second sample (cFPG2) was taken on another day, 
followed by a venous sample (vFPG) if cFPG2 >6.0 mmol/l ánd cFPG1 or 2 ≥7.0 
mmol/l. 
Results Of 3,724 at-risk patients invited for a cFPG1, 3,335 (90%) returned for the 
measurement. Ultimately, in 125 (4%) of them a vFPG was measured. In 101 out of 
125 patients the vFPG was ≥7.0 mmol/l, giving a positive predictive value of our 
protocol of 81%.
Conclusion A stepwise screening protocol including two subsequent capillary 
blood glucose measurements from a portable blood glucose meter is well applicable 
in screening for type 2 diabetes in primary care.
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Introduction
The fasting plasma glucose (FPG) test is an interesting and pragmatic tool for screening 
for type 2 diabetes in primary care, especially when measured in capillary whole 
blood using a portable blood glucose meter.1-5 As the day-to-day variability of FPG 
is about 15%,6 in asymptomatic subjects the diagnosis of diabetes should only be 
made after confirmation by a second test on a subsequent day.7,8 However, while 
portable meters are accurate enough for (self-) monitoring of blood glucose,9-11 its 
use in screening is only accepted if followed by a venous measurement.3,5 Therefore 
a stepwise screening strategy might improve the validation of the portable blood 
glucose meter. 
 The aim of this study was to evaluate the applicability (positive predictive value) 
of a stepwise protocol in opportunistic screening for type 2 diabetes in primary care 
using a portable blood glucose meter.
Methods
The present study is part of an opportunistic screening programme for type 2 
diabetes in primary care – the Diabscreen study. Patients were recruited from 11 
general practices (total practice population n = 49,229) in the Netherlands.12-14 All 
patients at risk for undiagnosed type 2 diabetes, aged ≥45 and ≤75 years, who were 
listed with these practices were considered for the study. At-risk was defined as 
having one or more diabetes risk factors, derived from the American Diabetes 
Association’s recommendations in screening for type 2 diabetes: a family history 
of diabetes (parent and/or brother and/or sister with diabetes), hypertension, 
cardiovascular disease (myocardial infarction, heart failure, atrial fibrillation, 
stroke, peripheral vascular disease), lipid metabolism disorders, obesity (BMI >27), 
and a history of gestational diabetes mellitus (GDM).3 As described in detail elsewhere, 
we translated these risk factors into a set of matching ICPC and ATC codes. This 
enabled us to mark the patients’ risk status (risk/no risk) in the electronic medical 
record.15 From 2000 to 2001, the GPs verified and in case of missing data completed 
the patients’ risk profile during usual care. At-risk patients were invited for a 
capillary FPG measurement. 
 Samples were taken from capillary whole blood using a Gluco Touch® (LifeScan 
Benelux, Beerse, Belgium) plasma calibrated portable blood glucose meter. 
 Patients were suspected for having undiagnosed type 2 diabetes when having 
a capillary FPG >6.0 mmol/l (110 mg/dl; the cut point for impaired fasting glucose 
(IFG)) on two separate days, with at least one of these values being ≥7.0 mmol/l (126 
mg/dl; the cut-off value for diabetes).7
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For that reason, all patients with an initial value >6.0 mmol/l were invited for a 
second capillary measurement (cFPG2). This was immediately followed by a venous 
sample (vFPG) if at least one of the capillary measurements was ≥7.0 mmol/l.
 This sample was sent to a central laboratory for further analysis in a Roche/
Hitachi analyzer using the glucose oxidase method (the reference method). For the 
present study, we included those patients (n = 125) who completed the screening 
protocol (cFPG1, cFPG2 and vFPG).
 Data were analyzed with SPSS 14.0.2 for Windows (SPSS Inc., Chicago, IL, USA). 
To compare the performance of the portable blood glucose meter to the reference 
method, we calculated the correlation coefficient and the limits of agreement as 
described by Bland and Altman.16 As a main outcome, we calculated the positive 
predictive value of our screening protocol. 
Results
In the 11 participating practices, 49,229 patients were registered, of whom 14,457 
were aged ≥45 and ≤75 years. In 876 (6%) patients, diabetes mellitus had already 
been diagnosed, leaving 13,581 patients for the study. During usual care, the 
participating GPs were able to invite 3,724 at-risk patients for further screening by 
means of FPG measurement (Figure 1). Of those invited, 3,335 (90%) returned for 
the cFPG1 measurement and entered the stepwise screening protocol. Their 
baseline characteristics are shown in Table 1. In 496 (13%) patients a cFPG2 and in 
125 (4%) a vFPG was performed according to the stepwise protocol.
 So, as shown in Figure 1, 125 patients completed the stepwise protocol and had 
three measurements taken (cFPG1, cFPG2 and vFPG). Fifty-seven patients (46%) 
were male, mean age was 58.8 ± SD 8.5 years. Mean cFPG1, cFPG2 and vFPG were 
8.7 ± 3.1, 8.3 ± 2.3 and 8.6 ± 2.3 mmol/l, respectively. Mean BMI was 30.2 ± 4.6.
Fasting capillary and venous glucose values were highly correlated, with the latter 
being systematically higher. For cFPG2 and vFPG (both not Normally distributed), 
the Spearman’s rank correlation coefficient was 0.77 (p = 0.01).
 Despite the high correlation between the two methods, they differed significantly. 
The mean difference (vFPG minus cFPG2) was 0.35 mmol/l (95% CI 0.17-0.53, p 
<0.001; limits of agreement (=mean difference ± 1.96 SD) = -1.65 to 2.35 mmol/l). For 
the diagnostic range of 6.0-8.0 mmol/l (n = 73), the mean difference was 0.31 
mmol/l (95% CI 0.16-0.46, p <0.001; limits of agreement -0.96 to 1.59 mmol/l).
 In 101 out of 125 patients the vFPG was ≥7.0 mmol/l, giving a positive predictive 
value (PPV) of our protocol of 81%.
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Discussion
Our stepwise screening protocol performed well using a portable blood glucose 
meter. The use of two capillary measurements with a combination of two cut-off 
points (>6.0 and ≥7.0 mmol/l) enabled us to considerably reduce the number of 
patients in whom we needed to assess a laboratory blood glucose value. The PPV of 
our protocol was 81%. 
One of the strengths of this study was that capillary blood samples were taken 
during daily routine practice in the patients’ local general practice by the practice 
assistants, without any further support e.g. from trial nurses. Another strength of 
the study was the practice setting: although related to a university department of 
general practice, the participating general practices were all standard community 
practices with a population representative of the Dutch population and a diabetes 
prevalence equal to that in the Netherlands. A possible limitation was that only 
patients that visited the GP were invited for screening (referral bias). Also, we did 
not take three samples (two capillary and one venous) from all study participants 
and therefore could not calculate sensitivity and specificity. However, the focus 
was on testing the applicability of our stepwise protocol in identifying patients 
with undiagnosed type 2 diabetes (positive predictive value).
Table 1   Baseline characteristics of the patients entering the stepwise screening 
protocol (n = 3,335 unless otherwise indicated)
Gender (% male) 42.3
Mean age (years ± SD) 58.2 ± 8.2
Mean cFPG1 (mmol/l ± SD) 5.5 ± 1.2
     cFPG1 6.1-7.0 mmol/l (%) 11.8
     cFPG1 ≥7.0 mmol/l (%) 5.2
Mean BMI (kg/m2 ± SD) 28.0 ± 4.5
     BMI >27 (%) (n = 3,110) 57.4
Hypertension (%) 24.4
Cardiovascular disease (%) 15.0
Lipid metabolism disorders (%) (n = 993) 32.1
Family history of diabetes (%) 38.6
History of GDM (%) (n = 609) 2.8
BMI = body mass index; cFPG1 = first capillary fasting plasma glucose; GDM = gestational diabetes mellitus.
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 As we could not consider the whole range of blood glucose values due to our 
screening protocol, the high correlation we found between capillary and venous 
blood glucose values was not as high as described in literature.10 The difference 
between the two methods has also been described before.10,17 Because of this 
difference, the use of portable blood glucose meters in diagnosing diabetes is 
debated.18 We found no opportunistic screening studies using a portable blood 
glucose meter. Nevertheless, studies of fasting capillary glucose screening have 
reported performances similar to those for fasting venous glucose tests.9 This has 
been confirmed by recently performed population-based screening studies using 
capillary blood glucose samples.19,20 One of these studies also used a portable blood 
glucose meter,20 but in both studies, samples were measured in a controlled 
laboratory setting. 
 In conclusion, our study showed that a stepwise screening protocol including 
two subsequent capillary blood glucose measurements from a portable blood 
glucose meter is well applicable in screening for type 2 diabetes in primary care. 
However, further research is needed to estimate the cost-effectiveness of our 
screening protocol, as well as more detailed testing of the sensitivity and specificity 
for our stepwise approach.
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Abstract
Purpose In screening for type 2 diabetes, guidelines recommend targeting high - 
risk individuals. Our objectives were to assess the yield of opportunistic targeted 
screening for type 2 diabetes in primary care and to assess the diagnostic value of 
various risk factors.
Methods In 11 family practices (total practice population = 49,229) in the Netherlands, 
we conducted a stepwise opportunistic screening program among patients aged 
45 to 75 years by (1) identifying high-risk individuals (≥1 diabetes risk factor) and 
low-risk individuals using the electronic medical record, (2) obtaining a capillary 
fasting plasma glucose measurement, repeated on a separate day if the value was 
greater than 6.0 mmol/l (110 mg/dl), and (3) obtaining a venous sample if both 
capillary fasting plasma glucose values were greater than 6.0 mmol/l and at least 1 
sample was 7.0 mmol/l (126 mg/dl) or greater. We calculated the yield (percentage 
of invited patients with undiagnosed diabetes), number needed to screen (NNS), 
and diagnostic value of the risk factors (odds ratio and area under the receiver 
operating characteristic curve).
Results We invited for a first capillary measurement 3,724 high-risk patients seen 
during usual care and a random sample of 465 low-risk patients contacted by mail. 
The response rate was 90% and 86%, respectively. Ultimately, 101 high-risk patients 
(2.7%; 95% confidence interval [CI], 2.2%-3.3%; NNS = 37) and 2 low-risk patients 
(0.4%; 95% CI, 0.1%-1.6%; NNS = 233) had undiagnosed diabetes (P <0.01). The 
prevalence of diabetes among patients 45 to 75 years old increased from 6.1% to 
6.8% as a result. Among diagnostic models containing various risk factors, a model 
containing obesity alone was the best predictor of undiagnosed diabetes (odds 
ratio = 3.2; 95% CI, 2.0-5.2; area under the curve = 0.63).
Conclusions The yield of opportunistic targeted screening was fair; obesity alone 
was the best predictor of undiagnosed diabetes. Opportunistic screening for type 2 
diabetes in primary care could target middle-aged and older adults with obesity.  
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Introduction
Primary care clinicians are encouraged to be more proactive in detecting and 
treating both diabetes and pre-diabetes.1 The recently updated standards of 
medical care of the American Diabetes Association (ADA) recommend testing 
adults of any age who are overweight or obese and have additional diabetes risk 
factors.2
 The main reason to recommend screening for type 2 diabetes is the disease’s 
long preclinical period of up to 12 years. The condition goes undiagnosed in 
one-third to one-half of all people with type 2 diabetes during this entire period, 
and they already have complications by the time of diagnosis.3 
 Starting treatment at an earlier stage might prevent or delay the development 
of diabetes complications. Studies have shown that in clinically detected (not 
screening-detected) diabetes, tight glycemic control can reduce progression of micro - 
vascular disease, and that treatment of hypertension and hyperlipidemia decreases 
cardiovascular risk.4 Screening for and treating prediabetes – impaired fasting 
glucose (IFG) and impaired glucose tolerance –  might prevent or slow the progression 
to diabetes and reduces the risk of cardiovascular disease.1,5 
 At present, however, randomised controlled trials have failed to show that earlier 
detection by screening reduces morbidity, mortality, or both among people with 
undiagnosed type 2 diabetes.4,6 There is also little knowledge about the ethical, 
psychological, and social consequences of screening results that are truly or falsely 
positive or negative, and there is no consensus on which screening tests to use and 
which diagnostic cut-off points are best. 7-9
 These considerations notwithstanding, screening for diabetes is encouraged 
nowadays. Targeting high-risk patients is recommended, as there is no evidence of 
a direct benefit of routine population-based screening for type 2 diabetes.2,4,10-12 As 
screening should also be a systematic and continuous process,7 opportunistic 
targeted screening might be a valuable screening method in primary care. This 
method entails screening high-risk individuals during usual care.6
 The pragmatic nature of opportunistic targeted screening enables initiation 
of further diagnostic testing and treatment of newly diagnosed with type 2 
diabetes. To investigate this approach, we performed a study of a stepwise opportunistic 
screening program embedded in daily routine care in family practices in the 
Netherlands, targeting high-risk patients – the Diabscreen study. In the analysis 
reported here, our objectives were to assess the yield of our screening program and 
the diagnostic value of the risk factors we used in the study.
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Participants and setting
Participants were recruited from 11 family practices in the Netherlands that were 
part of academic research networks of university departments of family medicine. 
The practices had a total practice population of 49,229 patients, cared for by 25 
family practitioners, and had not previously performed systematic screening for 
diabetes. Seven of the practices were from the Radboud University Nijmegen 
Medical Centre,13 2 were from Maastricht University,14 and 2 from the Amsterdam 
VU University Medical Centre.15 We considered for inclusion in the study all 
patients aged 45 to 75 years inclusive who were listed with these practices and 
were not known to have diabetes. In the Netherlands, every individual in the 
population is registered with a family practitioner, usually the same one for many 
years. Patients need a referral by a family practitioner to consult a specialist.
 All practices used an electronic medical record (EMR) with the same software 
(Promedico ICT Inc, Nieuwegein, the Netherlands) containing relevant medical 
information, such as medical history, diagnoses, medication use, and referrals. 
Coding of diagnoses was based on the electronic version of the International 
Classification of Primary Care (ICPC) codes.16 Prescribed medication was coded 
according to Anatomical Therapeutic Chemical (ATC) codes.17 
 In our study, patients were defined as having undiagnosed type 2 diabetes if 
they had a venous fasting plasma glucose (FPG) value of at least 7.0 mmol/l (126 mg/
dl). They were defined as having IFG if they had a venous FPG value of greater than 
6.0 mmol/l (110 mg/dl) and less than 7.0 mmol/l.18,19 We did not study impaired 
glucose tolerance, because our pragmatic screening protocol involved only FPG 
testing and no an oral glucose challenge.
 Ethical approval for the study was obtained by the Radboud University Nijmegen 
Medical Centre ethics committee.
Screening program
Our opportunistic screening program consisted of a stepwise screening procedure: 
(1) using the EMR, identification of high-risk and low-risk individuals; (2) a first 
capillary FPG measurement and, if indicated by the result, a second one; and (3) if 
indicated by that result, a venous FPG. 
 Patients were considered to be at high risk for undiagnosed type 2 diabetes in 
case of one or more of the following diabetes risk factors, derived from the ADA 
recommendations in screening for type 2 diabetes2: a family history of diabetes 
(defined as diabetes in a parent, brother, or sister, or some combination thereof), 
hypertension, cardiovascular disease (myocardial infarction, heart failure, atrial 
fibrillation, stroke, peripheral vascular disease), lipid metabolism disorders, obesity 
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(body mass index >27 kg/m2), and a history of gestational diabetes mellitus.2,11 
 We translated these risk factors into a set of matching ICPC and ATC codes.20 
Using a computerized cross-sectional analysis of ICPC and ATC information for 
each patient from the practices’ EMR, we determined the patients’ diabetes risk 
status (high vs low) and entered it in the EMR. During a usual care consultation in 
the following year, the EMR reminded the family practitioners to verify and, in 
case of missing data, complete the patients’ risk profile and to invite high-risk 
patients for an FPG measurement. As part of daily practice, an appointment for 
this test was recorded in the practice schedule. There were no further reminders.
 In addition, to assess the yield of opportunistic screening among low-risk 
patients, from each participating practice, we also invited for FPG measurement a 
random sample of low-risk patients: patients from the same age-group, but without 
any of the risk factors listed above. On the basis of an expected prevalence of 
undiagnosed type 2 diabetes of 0.5%,21 an intraclass correlation coefficient of 0.03, 
and a desired precision of 1%, we calculated a required sample size of 380 low-risk 
patients. These patients were randomly selected from a list of low-risk patients and 
subsequently invited by mail to visit the practice for screening. 
Our stepwise screening protocol was based on cut-off points used for IFG and 
diabetes.22 All patients with an initial capillary FPG of greater than 6.0 mmol/l 
were invited for a second capillary measurement on another day. This second 
measurement was immediately followed by a venous FPG measurement  if both 
capillary measurements were greater than 6.0 mmol/l and at least 1 was 7.0 mmol/l 
or greater. 
Measurements
Measurements were made in the patients’ own family practice by the regular 
practice assistants. Capillary samples were taken using a Gluco Touch plasma 
calibrated capillary blood glucose meter (LifeScan Benelux, Beerse, Belgium). 
Before the start of the study, all participating practices received new meters, which 
were checked and adjusted, if necessary, by the manufacturer. The practice 
assistants were trained in using the meters. Venous samples were sent to a central 
laboratory for further analysis in a Roche/Hitachi chemical analyzer (Roche 
Nederland BV, Woerden, the Netherlands), using the glucose oxidase method.
Data analysis
We analyzed data with SPSS 16.0 for Windows (SPSS Inc, Chicago, Illinois). 
Statistical analysis was performed using the χ2 test for categorical data and the 
Student t test or Kruskal-Wallis test for means where appropriate. We considered a 
P value <.05 to be significant.
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We calculated the yield of our screening program (the percentage of invited 
patients found to have undiagnosed type 2 diabetes); the number of patients who 
would need to be invited for screening in order to identify 1 patient with 
undiagnosed type 2 diabetes, or number needed to screen (NNS); and the change 
in diabetes prevalence among the study population resulting from the program.
We examined possible interactions between the risk factors by calculating the 
correlation coefficients. Then, we quantified their association with the presence or 
absence of undiagnosed diabetes using univariate logistic regression analysis. 
Variables with a P value ≤0.15 were included in multivariate binary logistic 
regression analysis to determine their independent contribution to the risk of 
undiagnosed type 2 diabetes. Using the backward stepwise (likelihood ratio) 
method, excluding variables one by one, we were able to produce diagnostic models 
with an area under the receiver operating curve (AUC).
Results
The 11 participating practices had 49,229 registered patients (2,500-9,750 per 
practice), of whom 14,457 (957-1,831 per practice) were aged 45 to 75 years (Figure 1). 
The prevalence of known diabetes before our screening program was 6.1%, leaving 
13,581 patients for the study. During the 1-year study period, 5,277 (39%) of these 
patients had an encounter with a family practitioner during which screening was 
discussed. Risk assessment indicated that 3,724 (71%) were at high risk for diabetes 
and 1,553 (29%) were at low risk; 90% of the high-risk patients and 86% of the 465 
invited low-risk patients returned for a first capillary FPG measurement after 
invitation. Sex and mean age did not differ significantly between high-risk and 
low-risk patients, but mean FPG was slightly higher in the former group (Table 1). 
High-risk patients
A second capillary FPG was performed in 496 high-risk patients, or 88% of those 
invited (Figure 1). According to our protocol, 169 (5%) were eligible for venous FPG 
measurement immediately after the second capillary FPG measurement. A venous 
sample was collected in 125 (74%) of these patients but not in 44 (26%). In the latter 
group, the second capillary FPG more often was 6.1 to 7.0 mmol/l, but other char-
acteristics did not differ significantly (Table 2). Of the 125 patients with a venous 
sample, 81% had undiagnosed type 2 diabetes, 16% had IFG, and 3% had a normal 
fasting glucose level. These groups differed significantly in terms of mean FPG 
values and the prevalence of lipid metabolism disorders (Table 3).
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Low-risk patients
In the low-risk group, only 2 patients had undiagnosed type 2 diabetes and 1 
patient had IFG (Figure 1). The characteristics within each subgroup are displayed 
in Table 3. Further analysis was not possible in this group because of to the small 
number of patients.
Yield of the screening program
We found undiagnosed type 2 diabetes in 101 high-risk patients and 2 low-risk 
patients. These values corresponded to 2.7% of high-risk patients (95% confidence 
interval [CI], 2.2%-3.3%; NNS = 37) vs 0.4% of low-risk patients (95% CI, 0.1%-1.6%; 
NNS = 233) invited for screening (P <0.01). As a result of the screening program, the 
prevalence of known diabetes among patients aged 45 to 75 years in the study 
practices increased from 6.1% (876 patients) to 6.8% (979 patients).
Table 1   Baseline characteristics of high-risk and low-risk patients in whom a first 
capillary fasting plasma glucose level was measured
High-risk patients Low-risk patients
Characteristic n = 3,335 n = 398 P
Sex (male), No. (%) 1,411 (42.3) 168 (42.2) 0.97
Age, mean (SD), years 58.2 (8.2) 57.5 (7.2) 0.07
cFPG1
cFPG1, mean (SD), mmol/l 5.5 (1.2) 5.2 (0.6) <0.001
cFPG1 6.1-7.0 mmol/l, No. (%) 394 (11.8) 16 (4.0) <0.001
cFPG1 ≥7.0 mmol/l, No. (%) 172 (5.2) 6 (1.5) <0.001
BMIa
BMI, mean (SD), kg/m2 28.0 (4.5) 23.5 (2.2) <0.001
BMI >27 kg/m2, No. (%) 1,786 (57.4) 0 –
Risk factors
Hypertension, No. (%) 814 (24.4) 0 –
Cardiovascular disease, No. (%) 499 (15.0) 0 –
Lipid metabolism disorders,b No. (%) 319 (32.1) 0 –
Family history of diabetes, No. (%) 1,288 (38.6) 0 –
History of GDM,c No. (%) 17 (2.8) 0 –
BMI = body mass index; cFPG1 = first capillary fasting plasma glucose; GDM = gestational diabetes mellitus. 
a Missing = 225. b Missing = 2,342. c Missing = 2,726.
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4
Diagnostic value of the risk factors
There were significant but no relevant correlations between the risk factors. For 
example, the Spearman rank correlation coefficient of obesity with hypertension 
was 0.08 with P <.01 (data not further shown).
 Univariate logistic regression analysis showed that the odds of undiagnosed 
type 2 diabetes were significantly higher among patients who were obesity (odds 
ratio [OR] = 3.2; 95% CI, 2.0-5.2) or had hypertension (OR = 2.5; 95% CI, 1.6-3.8) 
(Table 4). In contrast, a family history of diabetes was not significantly associated 
with undiagnosed diabetes (OR = 1.4; 95% CI, 0.9-2.1). Because of the large number 
of missing data, lipid metabolism disorders and history of gestational diabetes 
mellitus were not included in the analysis. 
Table 2   Characteristics of high-risk patients eligible for venous FPG measurement, 
comparing patients with and without a venous sample
Patients  with 
venous sample
Patients without 
venous sample
Characteristic n = 125 n = 44 P
Sex (male), No. (%) 57 (45.6) 23 (52.3) 0.45
Age, mean (SD), years 58.8 (8.0) 58.5 (8.1) 0.87
cFPG measurements
cFPG1, mean (SD), mmol/l 8.7 (3.1) 8.4 (2.8) 0.59
cFPG2, mean (SD), mmol/l 8.3 (2.3) 7.8 (2.1) 0.23
cFPG1 6.1-7.0 and cFPG2 ≥7.0, No. (%) 28 (22.4) 6 (13.6) 0.21
cFPG1 ≥7.0 and cFPG2 6.1-7.0, No. (%) 22 (17.6) 21 (47.8) <0.001
cFPG1 ≥7.0 and cFPG2 ≥7.0, No. (%) 75 (60.0) 17 (38.6) 0.01
BMI, mean (SD), kg/m2 30.2 (4.6) 31.0 (6.9) 0.39
Risk factors
Hypertension, No. (%) 49 (39.2) 15 (34.1) 0.55
Cardiovascular disease, No. (%) 22 (17.6) 5 (11.4) 0.33
Lipid metabolism disorders,a No. (%) 12 (33.3) 3 (21.4) 0.41
Family history of diabetes, No. (%) 58 (46.4) 17 (38.6) 0.37
History of GDM,b No. (%) 0 0 –
BMI = body mass index; FPG = fasting plasma glucose; cFPG1 = first capillary fasting plasma glucose; cFPG2 
= second capillary fasting plasma glucose; GDM = gestational diabetes mellitus. a Missing = 94 with venous 
sample; 30 without venous sample. b Missing = 100 with venous sample; 26 without venous sample
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4
 Multivariate binary logistic regression analysis showed that obesity was the 
best predictor of undiagnosed type 2 diabetes: 76.8% of those with the disease were 
obese (AUC = 0.63; 95% CI, 0.58-0.68) (Table 5). Hypertension and family history of 
diabetes were poorer predictors.
Table 4   Univariate analysis of the association between diabetes risk factors and the 
odds of undiagnosed type 2 diabetes
Undiagnosed diabetes
Risk factor
Yes, No. (%) 
n = 95
No, No. (%) 
n = 3,379
Odds ratio
(95% CI) P
Sex (male) 46 (48.4) 1,431 (42.3) 1.3 (0.9-1.9) 0.24
Age >60 years 45 (47.4) 1,406 (41.6) 1.3 (0.8-1.9) 0.26
Hypertension 37 (38.9) 691 (20.4) 2.5 (1.6-3.8) <0.001
Cardiovascular disease 16 (16.8) 429 (12.7) 1.4 (0.8-2.4) 0.23
Obesity (BMI >27 kg/m2) 73 (76.8) 1,713 (50.7) 3.2 (2.0-5.2) <0.001
Family history of diabetes 41 (43.2) 1,212 (35.9) 1.4 (0.9-2.1) 0.15
BMI = body mass index; CI = confidence interval. Note: Missing = 259.
Table 5   Multivariate analysis of the association between diabetes risk factors and 
the odds of undiagnosed type 2 diabetes and diagnostic performance
Model
Odds ratio
(95% CI) P
Undiagnosed 
diabetes,
No. (%)
n = 95 AUC (95% CI)a
Model 1 12 (12.6) 0.54 (0.48-0.61)
Obesity (BMI >27 kg/m2) 3.1 (1.9-5.0) <0.001 – –
Hypertension 2.3 (1.5-3.5) <0.001 – –
Family history of diabetes 1.4 (1.0-2.2) 0.09 – –
Model 2 30 (31.6) 0.60 (0.54-0.66)
Obesity 3.0 (1.9-4.9) <0.001 – –
Hypertension 2.3 (1.5-3.5) <0.001 – –
Model 3 73 (76.8) 0.63 (0.58-0.68)
Obesity 3.2 (2.0-5.2) <0.001 – –
AUC = area under the receiver operating characteristic curve; BMI = body mass index; CI = confidence interval. 
Note: Only risk factors with P ≤0.15 in Table 4 were included. a An AUC of 0.50 means that the model does 
not predict the outcome better (more accurately) or worse (less accurately) than random guess; an AUC 
greater than 0.50 means that the prediction is better than random, and an AUC less than 0.50 means that the 
prediction is worse than random.T
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Discussion
The yield of our opportunistic targeted screening program was fair: in 1 year we 
identified undiagnosed type 2 diabetes in 101 high-risk patients invited for 
screening (2.7%, NNS = 37). This number represents 30% of cases of known diabetes, 
considering that 39% of the study population had an encounter with a family 
practitioner (39% of 876 patients previously known to have diabetes = 342, and 
101/342 = 30%). The yield of screening in low-risk patients was, as expected, only 
0.4% (NNS = 233). The response rate for the capillary measurements was high, at 
about 90%. As a result of the screening program, the prevalence of known diabetes 
among our patients aged 45 to 75 years increased from 6.1% to 6.8%. Of the ADA 
diabetes risk factors, obesity was the best predictor of undiagnosed type 2 diabetes.
The main strength of the study was the setting. High-risk patients were invited for 
screening during daily routine practice in the patients’ local family practice by 
their own family practitioner. Capillary blood samples were taken by the practice 
assistants, without any further support (eg, from trial nurses). Although patients 
had to return in a fasting state for the capillary FPG measurements, they were 
highly willing to do so. And although all participating family practices were 
related to a university department of family medicine, they were standard 
community practices with a population representative of the Dutch population 
and a diabetes prevalence equal to that in the Netherlands.13-15,23  Because the 
Dutch system of primary health care provides for universal access and continuity 
of patient registration, we were able to use the family practice EMR in a continuous 
screening program. 
 Our screening approach calls for the identification of individual risk factors 
during a regular consultation. To the extent possible, we used available information 
from the EMR, which is based on the ICPC. A limiting factor is that not all risk 
factors are included in the ICPC at this time; therefore, we had to ask patients 
about their risk factors to confirm their status.20 Our study supports the relevance 
of routine inclusion of risk factors in the EMR and the importance of extending 
the ICPC to include this information.
 A possible limitation was that we used the FPG test rather than the oral glucose 
tolerance test. The latter test consists of an FPG measurement plus a 2-hour plasma 
glucose measurement, and has been considered to be the criterion standard in 
diagnosing diabetes. The FPG test is, nevertheless, recommended for screening in 
primary care as it is easier and faster to perform, more convenient and acceptable 
to patients, and less expensive.2,24
 Our focus was on testing the applicability of our stepwise protocol during 
usual care; therefore, we did not collect 3 blood samples (2 capillary and 1 venous) 
from all study participants. With an 81% concordance between identification for 
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venous sampling and an undiagnosed type 2 diabetes outcome in high-risk patients 
(positive predictive value = 81%), our protocol was very useful. Since this protocol 
was designed to screen for undiagnosed type 2 diabetes, few patients who underwent 
venous sampling were found to have IFG. 
 In 26% of our high-risk patients eligible for a venous sample, this measurement 
was not performed. Considering the high level of compliance with the capillary 
measurements, the general lack of significant differences between patients with 
a venous measurement and those without, and the requirement by the protocol 
that the venous sample be obtained immediately after the second capillary 
measurement, we believe that the missing venous samples were mainly due to 
protocol factors (eg, misinterpretation – willingly or not – by the practice assistants) 
instead of patient factors. The fact that high-risk patients without a venous sample 
more often had a second capillary FPG of 6.1 to 7.0 mmol/l, supports this 
assumption. Instead of giving assistents a flowchart with all possible combinations 
of glucose outcomes (not described) as we did in the study, we now believe it would 
have been more helpful if we had given them the simple algorithm mentioned in 
the Methods section. We estimate that if compliance had been 100%, the number 
of newly diagnosed cases of diabetes among high-risk patients could in fact have 
been 136, giving an even lower NNS of 28.
 The portable glucose meters we used are user-friendly and readily available in 
primary care. A potential drawback is their variability,25 and consequent risk of 
false-positive and false-negative outcomes. Our stepwise approach, in which 
patients with glucose levels above the threshold underwent measurement again, 
did address the problems of false-positive results.22 To address false-negative 
results, the procedure must be repeated, for example, every 3 years, as recommended 
by the ADA.2
 Since we wanted to perform a screening program embedded in daily care 
without any further support, we did not specifically study disadvantages or harms, or 
cost-effectiveness of our opportunistic screening program, nor did we specifically 
investigate acceptability of the screening procedure. As the program was embedded 
in daily care and the patient attendance rate was 90%, however, we believe we can 
conclude that it was inexpensive and feasible. Further research is needed, though.
 Several diabetes screening studies have been described in the literature. Smith 
et al.26 undertook an opportunistic diabetes screening study performed in family 
practice using a questionnaire presented to patients who were waiting to see their 
doctor. Their participation rate was also high (93%), and 43% of patients had at 
least 2 risk factors. If performed continuously or repeated regularly, such an 
approach might provide more complete and up-to-date information on a patient’s 
risk status in the EMR, improving the identification of high-risk patients for 
screening purposes.
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 Greaves et al.27 showed that identifying patients with type 2 diabetes and IFG 
using data stored in family practice databases was feasible (NNS = 21-38 for type 2 
diabetes), but instead of using an opportunistic approach, they invited high-risk 
patients (those aged >50 years and with a body mass index ≥27 kg/m2) to screening 
clinics run by trained practice nurses. The response rate was 61%. Nevertheless, 
the simple screening system they describe – like ours – would promote efficient 
use of scarce primary health care resources, especially when set up as part of a 
broader screening program to reduce cardiovascular disease. 
 In a cross sectional study in a local family practice, Lawrence et al.21 showed 
that screening of invited patients whose sole risk factor for diabetes is age older 
than 45 years has a low yield. In this group, they found a diabetes prevalence of 
just 0.2%. Among individuals with 1 or more other risk factors, the figure increased 
to 2.8%.  Both prevalences are comparable to ours. 
 Recently, a population-based screening program for type 2 diabetes was 
performed in the Netherlands.12 Although the increase in diabetes prevalence 
achieved with the program (from 6.1% to 7.0% among people aged 50 to 70 years) 
was comparable to ours, the response to an invitation to glucose testing was 31% 
and the yield only 1%. The authors concluded that opportunistic screening might 
be more appropriate. 
 Primary care practices often have large patient populations, underscoring the 
need for a targeted approach to screening. In our family practices, more than 
two-thirds of middle-aged and older study patients eligible for screening were at 
high risk. But largely because of the stepwise protocol, the yield of our opportunistic 
targeted screening method was fair. 
 In a recently updated statement,28 the US Preventive Services Task Force 
recommends screening for type 2 diabetes in asymptomatic adults with hyper -
tension. As part of an assessment of cardiovascular disease risk, clinicians should 
also screen for diabetes to adequately assess patients’ risk for this condition as 
well.28 With ever greater integration of diabetes screening into cardiovascular risk 
management, opportunistic screening for type 2 diabetes in primary care could 
target the middle-aged and older adults with obesity. With this approach, the 
number of high-risk patients to be screened would be considerably reduced. A 
similar approach was found to be cost-effective.29 
 With an opportunistic targeted screening program like ours, diabetes screening 
in primary care can be performed systematically and continuously, with probably 
few drawbacks for both patients and health care workers, and with efficient use of 
resources. Further research is needed to estimate its cost-effectiveness and 
limitations. Also, sensitivity and specificity of our stepwise approach need to be 
studied.
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 In conclusion, the yield of opportunistic targeted screening in our study was 
fair, and obesity alone was the best predictor of undiagnosed diabetes. Our data 
confirm a low yield when low-risk individuals are screened. As diabetes screening 
is increasingly integrated into cardiovascular risk management, opportunistic 
screening for type 2 diabetes in primary care could target the middle-aged and 
older adults with obesity. 
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Age at initiation and frequency of screening to detect type 2 
diabetes: a cost-effectiveness analysis 
Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, 
Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ
The Lancet 2010; 375 (9723): 1365-1374
Abstract
Background No clinical trials have assessed the effects or cost-effectiveness of 
sequential screening strategies to detect new cases of type 2 diabetes. We used 
a mathematical model to estimate the cost-effectiveness of several screening 
strategies. 
Methods We used person-specific data from a representative sample of the US 
population to create a simulated population of 325,000 people aged 30 years 
without diabetes. We used the Archimedes model to compare eight simulated 
screening strategies for type 2 diabetes with a no-screening control strategy. 
Strategies differed in terms of age at initiation and frequency of screening. 
Once diagnosed, diabetes treatment was simulated in a standard manner. We 
calculated the effects of each strategy on the incidence of type 2 diabetes, 
myocardial infarction, stroke, and microvascular complications in addition to 
quality of life, costs, and cost per quality-adjusted life-year (QALY). 
Findings Compared with no screening, all simulated screening strategies 
reduced the incidence of myocardial infarction (3-9 events prevented per 1000 
people screened) and diabetes-related microvascular complications (3-9 events 
prevented per 1000 people), and increased the number of QALYs (93-194 
undiscounted QALYs) added over 50 years. Most strategies prevented a significant 
number of simulated deaths (2-5 events per 1000 people). There was little or no 
effect of screening on incidence of stroke (0-1 event prevented per 1000 people). 
Five screening strategies had costs per QALY of about US$10,500 or less, whereas 
costs were much higher for screening started at 45 years of age and repeated 
every year ($15,509), screening started at 60 years of age and repeated every 3 
years ($25,738), or a maximum screening strategy (screening started at 30 years 
of age and repeated every 6 months; $40,778). Several strategies differed 
substantially in the number of QALYs gained. Costs per QALY were sensitive to 
the disutility assigned to the state of having diabetes diagnosed with or without 
symptoms.
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Correspondence
Richard Kahn and colleagues (April 17, p 1365)1 used a mathematical model to 
show that screening for type 2 diabetes is cost-effective when started at the age of 
30-45 years and repeated every 3-5 years. They conclude that the cost per quality-
adjusted life-year would be improved if screening was done opportunistically and 
by risk assessment before glucose testing. They state that there are no clinical 
trials against which to validate their model.
 In the Diabscreen study,2 an opportunistic screening programme for type 2 
diabetes in patients aged 45-75 years in primary care in the Netherlands, we used 
the family practice electronic medical record (EMR) for risk assessment before 
glucose testing. Risk was marked in the EMR. In 1 year, physicians succeeded in 
starting stepwise fasting glucose testing during usual care in 39% of the patients. 
First response rate was 90%. The screening yield was much higher in high-risk 
than in low-risk patients (number needed to screen 37 versus 233). Obesity was the 
best predictor of undiagnosed diabetes (odds ratio 3.2). This finding is in line with 
one of the American Diabetes Association’s recommendations to screen all adults 
aged 45 years and older with a body-mass index of 25 or greater.3
 Although not a trial, our clinical findings clearly show that opportunistic 
screening in primary care is feasible. Middle-aged and older adults at high risk, 
especially those with obesity, can be targeted effectively. An EMR can be most 
helpful for identification of high-risk patients and also in supporting repeated 
screening, but this requires universal access and continuity of patient registration.
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Interpretation In the US population, screening for type 2 diabetes is cost-effective 
when started between the ages of 30 years and 45 years, with screening repeated 
every 3-5 years. 
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Abstract
Background In type 2 diabetes, educational interventions that target differences 
between patients’ and partners’ illness perceptions have been advocated. 
Objective To investigate how the route to diagnosis of type 2 diabetes (through 
screening versus clinical symptoms) affects illness perceptions of patients and 
their partners. 
Methods In a cross-sectional study, we enrolled patients aged 40-75 years from 
general practices in the Netherlands with a new diagnosis of type 2 diabetes (≤3 
years), detected by either screening (n = 77) or clinical symptoms (n = 32). Patients 
and their partners each completed a postal Brief Illness Perception Questionnaire 
(Brief IPQ), and up-to-date clinical data were obtained from their GP. The Brief IPQ 
scores of the screening and clinical diagnosis groups were compared for both 
patients and partners, and multiple variable linear regression models with Brief 
IPQ scores as outcomes were developed.
Results The route to diagnosis did not appear to have a strong influence on patients’ 
illness perceptions, but did influence illness perceptions of their partners. Partners 
of patients diagnosed through screening perceived greater consequences for their 
own life, had a stronger feeling that their patient-partners had control over their 
diabetes, were more concerned about their partners’ diabetes, and believed that 
their patient-partners experienced more diabetes symptoms, compared with 
partners of patients who were diagnosed through clinical symptoms.
Conclusions The route to diagnosis of type 2 diabetes has a greater impact on the 
illness perceptions of partners than that of patients. Professionals in diabetes 
education and treatment should consider these differences in their approach to 
patient care.
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Introduction
Screening for type 2 diabetes is recommended because it may reduce the risk of 
vascular complications.1-4 Some questions remain unresolved, however, in particular 
regarding the psychological consequences of early detection and treatment of type 
2 diabetes.5 Although the psychological impact of a screening-based diagnosis of 
type 2 diabetes on patients is generally limited,6 intensive treatment following 
screen-detected diabetes has been shown to lead to higher levels of anxiety and 
lower self-efficacy in the first year after diagnosis, without an accompanying 
improvement in self-care.7
 Similarly to other chronic diseases, patients with type 2 diabetes must take 
personal responsibility for the management of their illness.8 Patients need to exercise 
and change their diet, take oral medications and may eventually require insulin 
injections, involving self-monitoring of blood glucose and insulin adjustments.1,9 
Although education provides the required knowledge, self-care behaviours are 
also influenced by beliefs – so-called illness perceptions – regarding type 2 diabetes.10 
 Illness perceptions include the following cognitive illness representations: 
consequences (beliefs about effects and impact), timeline (course and duration), 
personal control (own control over management), treatment control (outcome 
expectancies of treatment and recommended advice), identity (symptoms and 
label attributed to illness) and cause (perceived cause of the illness). Emotional 
representations (concern and emotions) and illness coherence (overall under-
standing) are also considered to be illness perceptions.11 
 Perceptions of personal control and an understanding of diabetes appear to 
be particularly important: studies have shown that an increased appreciation 
of these factors by patients are associated with better adherence to diet, exercise 
and medications, and with better blood glucose control, lower interference with 
social and personal functioning, fewer negative feelings and a more positive 
attitude towards diabetes.12,13 Evidence exists to support the contention that illness 
perceptions can be improved through targeted intervention and that these changes 
may also impact on glycaemic control.11
 As most type 2 diabetes self-care occurs at home, illness perceptions of family 
members, in particular the partner, play an important role in adaptation to the 
disease and in disease outcome.14 Patients with type 2 diabetes feel greater personal 
control compared with their partners but show a poorer understanding of their 
condition.15 Partners generally perceive diabetes as being more serious and as 
having a greater impact on daily life, whereas patients are often unaware of this 
heightened concern and have a more relaxed approach to living with the disease.16 
Gender can also affect illness perceptions of chronic diseases, an example of which 
is that male patients with coronary heart disease often attribute their condition to 
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risk behaviours, whereas female patients often identify stress as the cause.17 The 
psychological adjustment of female rheumatoid arthritis patients is improved 
when a husband shares optimistic beliefs regarding personal control, illness 
coherence and consequences.18 The considerations above suggest that interventions 
targeting differences and aiming to improve congruence in the illness perceptions 
of patients and partners, together with the development of a personalized plan 
to improve diabetes management, may be important in diabetes education and 
treatment.19 
 In this exploratory study, we hypothesized that the route to diagnosis of type 
2 diabetes – by screening in asymptomatic individuals or by clinical signs or 
symptoms – may affect the illness perceptions of patients and partners, and thus 
may be an important factor to consider in diabetes education programmes. We 
therefore compared data from type 2 diabetes patients and their partners detected 
by screening with data from type 2 diabetes patients and their partners detected 
by clinical signs or symptoms in the same study period and setting. In addition, we 
explored the interaction between gender and screening. 
Methods
Participants and setting
We invited individuals aged 40-75 years, who were diagnosed with type 2 diabetes 
within the last 3 years and were married or living together with a partner, to 
participate in this cross-sectional questionnaire study.
 Couples were recruited via general practitioners in one of two ways: initially, 
a subset of respondents was recruited using leaflets and posters sent to a random 
sample of 875 general practices throughout the Netherlands (60 couples responded). 
To improve response, we recruited additional couples from general practices 
participating in a practice-based research network (n = 47 couples, response rate 
44%)20,21 and from general practices participating in a diabetes research centre 
(n = 28 couples, response rate 30%).6 Patients with type 2 diabetes were treated in 
line with the Dutch general practice guidelines in all practices.1 Following 
completion of their participation form, each couple received both a ‘patient’ and a 
‘partner’  postal questionnaire. 
 We excluded 17 couples because either the patient or the partner did not wish 
to participate or failed to return the questionnaire. We excluded an additional 
seven couples because of an unclear route to diagnosis and a further two because 
the partner also had diabetes. In total, 109 heterosexual couples were enrolled in 
the study.
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Questionnaire
The questionnaire included demographic items (e.g. age, sex and educational 
level), questions regarding the disease (e.g. time since diagnosis, treatment) and 
questions about the participants’ relationship (e.g. duration of marriage).
 The patient questionnaire also included a question on the route to diagnosis. 
Depending on the answer, the couples were divided in two groups: (i) asymptomatic 
type 2 diabetes detected by (opportunistic) targeted screening (subsequently 
referred to as ‘screening’) or (ii) clinically diagnosed type 2 diabetes based on signs 
or symptoms (subsequently referred to as ‘clinical diagnosis’). 
 Illness perceptions were measured in patients and partners using questions 
from the Brief Illness Perception Questionnaire (Brief IPQ), a shorter version of 
the popular Revised Illness Perception Questionnaire (IPQ-R).11 The Brief IPQ is 
a validated questionnaire for rapid assessment of illness perceptions and was 
developed for use with ill or elderly people.22 It has nine single items without a 
total score (Box 1): items 1-8 are individually rated using a 0-to-10 visual response 
scale, with higher scores reflecting a stronger belief in or perception of the item, 
and item 9 probes the causes of diabetes by an open-ended question, asking the 
respondent to list up to three factors in rank order which he or she believes to have 
caused their diabetes. For partners, the questions were reformulated to address 
their specific perspectives. The partner questionnaire’s Cronbach’s alpha, a measure 
of internal reliability, was an acceptable 0.65. 
Clinical data
To compare baseline characteristics, we obtained recent clinical data from the 
patients’ own general practitioner (GP). These data were extracted from the 
electronic medical records by the GPs and included information derived from 
physical examination (body mass index and blood pressure), laboratory testing 
(hemoglobin A
1c
 and cholesterol), and glucose-lowering treatment (diet, oral 
agents, insulin).
Statistical analysis
Differences between the screening and clinical diagnosis groups were analysed 
in both patients and partners. Demographic and clinical characteristics were 
compared using the chi-square test for categorical data and the t-test for means. 
Descriptive statistics were used to calculate the mean Brief IPQ scores for patients 
and partners in both the screening and the clinical diagnosis groups. Responses to 
the causal item were grouped into categories, followed by a kappa measure of 
agreement within couples (generally ranging from 0 to 1.0, where larger numbers 
mean better agreement) and categorical analysis using chi-square tests.
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 To calculate the effect of a screening-based diagnosis versus clinical diagnosis 
on illness perceptions, we developed multiple variable linear regression models. 
In each model, we applied one of the Brief IPQ items (except item 9) as the dependent 
variable and the method of diagnosis as the independent variable. The unstandardized 
regression coefficient (ß), with matching 95% confidence interval (CI) and P value, 
was considered to be the absolute effect on the mean Brief IPQ score. Analyses were 
controlled for the additional independent variables such as age, sex, educational 
level, duration of diabetes, duration of marriage and insulin use. All analyses were 
carried out using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL), all were two sided 
and we considered a P value less than 0.05 to be significant.
Box 1   The Brief IPQ items with matching questions, adjusted for diabetes and 
partners (0-10 response scale, except item 9)a
1. Consequences How much does your (partner’s) diabetes affect your life?  
(0=no affect at all, 10=severely affects my life)
2. Timeline How long do you think your (partner’s) diabetes will continue?
(0=a very short time, 10=forever)
3. Personal control How much control do you feel you have (your partner has) over your 
(his/her) diabetes?  
(0=absolutely no control, 10=extreme amount of control)
4. Treatment control How much do you think the treatment can help your (partner’s) 
diabetes?
(0=not at all, 10=extremely helpful)
5. Identity How much do you (does your partner) experience symptoms from 
diabetes?
(0=no symptoms at all, 10=many severe symptoms)
6. Concern How concerned are you about your (partner’s) diabetes?
(0=not at all concerned, 10=extremely concerned)
7. Understanding How well do you feel you understand your (partner’s) diabetes?
(0=don’t understand at all, 10=understand very clearly)
8. Emotional 
response
How much does diabetes affect you emotionally? (e.g. does it make you 
angry, scared, upset or depressed?)
(0=not at all affected emotionally, 10=extremely affected emotionally)
9. Causal 
representation
Please list in rank-order the three most important factors that you 
believe caused your (partner’s) diabetes. 
The most important causes for me are:
1.   
2.  
3. 
a Cognitive illness representations: items 1, 2, 3, 4 and 5; emotional representations: items 6 and 8; illness 
comprehensibility: item 7; causal representation: item 9.
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Results
Our study included 109 patients with a new diagnosis of type 2 diabetes, of whom 
77 were detected by screening and 32 diagnosed by clinical signs or symptoms 
(Table 1). Although the two patient groups did not differ significantly in age or 
gender, clinically diagnosed patients were more often male. Partners in the 
screening group were more likely to be male, and partners in the clinical diagnosis 
group were significantly younger.
 Statistically significant differences in educational level and duration of 
marriage between the screening and clinical diagnosis patient groups included a 
mainly secondary educational level in the screening group, and more equally 
distributed educational level and a shorter duration of marriage in the clinical 
diagnosis group. Body mass index and use of glucose-lowering tablets and insulin 
were higher in the clinical diagnosis group but the differences were not statistically 
significant. All other characteristics were similar between groups. 
 With the exception of educational level, which was more often at primary or 
tertiary level in clinically diagnosed males than in females, no significant 
differences were found between male and female patients (data not shown).
 Brief IPQ mean scores and the results of linear regression models (with the 
adjusted absolute effect (β) of screening compared with clinical diagnosis on scores) 
are shown in Table 2. Brief IPQ mean scores within patients were comparable between 
the two groups, and no statistically significant effect of screening was found for 
any of the scores. Patients in both groups tended to recognize few effects on their 
own life and to believe that they were in control of their diabetes, reporting 
perceptions of symptoms, concern and emotional impact as low. 
 As for partners, however, significantly higher scores were found on four items 
in the screening group compared with the clinical diagnosis group: on the one 
hand, partners of screen-detected patients perceived greater consequences for 
their own life and had a stronger sense that their patient-partner was in control of 
his or her diabetes, but on the other hand, they were more concerned about their 
patient-partner’s diabetes and believed that their patient-partner experienced 
more symptoms of diabetes (Table 2). Significant differences appeared to be mainly 
caused by younger age (<60 years; Appendix 1) and by a longer duration of diabetes 
(>6 months since diagnosis; Appendix 2).
 Respondents’ answers to the open-ended question (causes of diabetes) could 
be categorized into three main, but not mutually exclusive, causes: lifestyle, 
hereditary factors, and older age. Couples showed some agreement regarding these 
causes (kappa 0.35, 0.42 and 0.31, respectively; data not shown). Comparing the 
study groups, the screening group was less likely to identify lifestyle as the cause 
of diabetes (70.6% versus 87.9%, respectively, P = 0.01) and more likely to believe 
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that hereditary factors also played a causal role (47.8% versus 31.0% in the clinical 
diagnosis group, P = 0.03). Older age as a cause of the disease was identified equally 
(24.3% of the screening group and 25.9% of the clinical diagnosis group, P = 0.81). 
The results of linear regression models by gender are presented in Table 3. Female 
patients detected by screening had a significantly greater belief in the effect of 
treatment compared with those in the clinical diagnosis group, whereas Brief IPQ 
scores within male patients were not significantly affected by the route to 
diagnosis. Female partners in the screening group were more concerned by their 
patient-partner’s diabetes and believed that their patient-partner experienced 
more diabetes symptoms following diagnosis, but they were optimistic about the 
duration of their partner’s diabetes. Male partners’ illness perceptions were 
comparable with male patients and showed no significant effect due to screening, 
although they appeared to perceive greater consequences for their own life and 
experience a higher emotional impact.
Table 3   Effect of screening on Brief IPQ scores, compared with clinical diagnosis, by 
gender
Patients Partners
Brief IPQ item
Male  
patients
β  (95% CI)a
Female 
patients
β  (95% CI)a
Female 
partners
β  (95% CI)a
Male  
partners
β  (95% CI)a
1.  Consequences for  
own life
-0.96  
(-2.77 to 0.86)
0.53  
(-2.39 to 3.46)
1.29  
(-0.55 to 3.13)
2.07  
(-1.13 to 5.26)
2.  Length of time  
diabetes will last
-0.05  
(-1.79 to 1.68)
1.80  
(-0.70 to 4.29)
-1.44  
(-2.77 to -0.10)b
-0.03  
(-2.20 to 2.15)
3.  Patient’s ability to  
control his/her diabetes
-0.15  
(-1.87 to 1.58)
2.06  
(-0.59 to 4.71)
1.32  
(-0.04 to 2.67)
0.87  
(-1.35 to 3.09)
4.  Belief in effect of 
treatment
-0.38  
(-1.73 to 0.97)
2.17  
(0.30 to 4.04)b
-0.22  
(-1.60 to 1.15)
-0.80  
(-2.96 to 1.36)
5.  Symptoms experienced  
by the patient
-0.88  
(-2.57 to 0.80)
-0.89  
(-4.17 to 2.39)
2.31  
(0.73 to 3.88)b
0.14  
(-2.70 to 2.98)
6.  Concern about  
patient’s diabetes
-0.34  
(-2.25 to 1.56)
-1.74  
(-4.83 to 1.35)
1.82  
(0.14 to 3.49)b
0.40  
(-2.66 to 3.45)
7.  Understanding of  
patient’s diabetes
0.98  
(-1.42 to 1.62)
0.59  
(-1.66 to 2.83)
0.63  
(-0.56 to 1.82)
-0.13  
(-1.56 to 1.31)
8.  Emotional impact, e.g. 
anger, fear, depression
0.21  
(-1.70 to 2.12)
-1.55 
(-4.68 to 1.58)
0.71  
(-1.05 to 2.47)
2.47  
(-0.53 to 5.47)
a Adjusted for age, educational level, duration of diabetes, duration of marriage and insulin use.
b Significant (P <0.05) relative to reference category (=clinical diagnosis group).
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Discussion
Summary of main findings
Patients diagnosed with type 2 diabetes shared similar illness perceptions, which 
appeared to be little affected by the route to diagnosis. 
 In contrast, the partners of patients who were detected by screening perceived 
greater effects on their own life compared with partners of patients identified by 
clinical diagnosis. However, partners in the screening group also showed a stronger 
belief in the ability of their patient-partner to control his or her diabetes and 
tended to overestimate ability to success-fully perform self-care. Female partners 
in the screening group were especially concerned about their partner’s diabetes 
and perceived more symptoms in their patient-partner.
 Couples showed some agreement when identifying the causes of diabetes, the 
screening group primarily focusing on hereditary factors and the clinical diagnosis 
group on lifestyle factors.
Strengths and limitations
The major strength of this study is that our findings are based on patient and 
partner data from regular general practices, rather than from a trial setting. 
Patients were diagnosed with type 2 diabetes in general practice and participants 
were recruited by their own GP. It therefore seems likely that the patterns found 
in this study are generally representative for primary care patients with type 2 
diabetes. Additional strengths derive from the use of a validated questionnaire 
and an acceptable internal reliability of the questionnaire when adapted for 
partners. Furthermore, as our analyses were controlled for age, sex, educational 
level, duration of marriage, duration of diabetes and insulin use, findings cannot 
be attributed to any of these variables.
 A limitation of the study may be the relatively small number of participants, 
resulting in a statistical power that may not have been sufficient to detect very 
small differences in illness perception scores among patient groups. Nevertheless, 
we were able to detect significant differences among partners, and the distribution 
of participants (screening group 71%, clinical diagnosis group 29%) was comparable 
with an earlier and larger study (n = 565; screening 64% versus clinical diagnosis 
36%).23
 Although many of our participants were recruited from general practices 
with an interest in diabetes and research, these practices are normal community 
practices with a population and diabetes prevalence rates representative of the 
general Dutch population. A selection bias due to a selective allocation to one 
study group is unlikely because patients were not randomized to a group but 
selected by the route to diagnosis. Patients in both study groups were all treated 
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according to the same practice guidelines during usual care.1 Volunteer or 
self-selection bias cannot be entirely ruled out, however, because response rates 
were low and some baseline characteristics differed between the study groups. We 
adjusted our data analyses for these differences so as to account for any possible 
bias.
 Another possible limitation is that three quarters of the patients participating 
in our study had a diagnosis older than 6 months, by which time many had already 
received education and treatment. However, time of diagnosis was comparable 
between the screen-detected and clinically diagnosed patient groups and similar 
low mean hemoglobin A
1c
 values reflected good glycaemic control in both groups. 
Nevertheless, and as stated in the section “Introduction”, dissimilarities in illness 
perceptions should still be targeted in order to improve self-care.
Comparison with existing literature
This study is the first to explore the effects of the route to diagnosis of type 2 
diabetes (through screening versus clinical diagnosis) on both patients’ and 
partners’ illness perceptions.
 The patients’ Brief IPQ scores in our study were comparable with those 
reported in literature.22 Furthermore, our findings that patients with a recent 
screening-based diagnosis of type 2 diabetes tend to report low emotional distress, 
low threat perceptions and a strong belief in personal control also agrees with 
previous studies.6,7 In addition, we found that illness perceptions were similar 
following a recent clinical diagnosis.
 Our data confirm that compared with patients, partners generally perceive 
diabetes as a more serious disease and as having a greater impact on daily life16 but 
indicate that these beliefs are especially prevalent following a screening-based 
diagnosis. 
 In an earlier study of illness perceptions that used the IPQ-R, patients with 
type 2 diabetes reported a greater sense of control over their diabetes than was the 
case with their partners.15 This contrasts with our findings, which showed that 
partners in the screening group had a stronger sense that their patient-partners 
were in control of their diabetes than that felt by the patients themselves. However, 
although the Brief IPQ and the IPQ-R are broadly comparable, the Brief IPQ 
personal control item was significantly associated with diabetes self-efficacy, in 
contrast to the IPQ-R personal control item, suggesting that the Brief IPQ may have 
an advantage in the area of control.22
 Finally, prospective research has shown that patients’ illness perceptions 
develop in the early stages of disease and that unless directly challenged by 
treatment or change in clinical state, they are likely to remain constant.24 In our 
study, significant differences in the Brief IPQ-scores of partners appeared to be 
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related to a longer diabetes duration in their patient-partners, perhaps indicating 
that partners’ illness perceptions may be less stable.
Implications for practice and research
We have shown that the screening route to the diagnosis of type 2 diabetes mainly 
impacts on the illness perceptions of patients’ partners. Partners of patients 
diagnosed through screening not only have greater negative beliefs regarding 
diabetes but also perceive enhanced personal control in their patient-partners. 
After 3 years, partners of screen-detected patients still appear to be more over - 
whelmed by the diagnosis than partners of clinically diagnosed patients and tend 
to believe, inaccurately, that their patient-partners have a high level of control 
over their diabetes.
 Our study yielded new and unexpected findings and stresses the importance 
of the partner’s role in diabetes education and treatment in daily primary care, 
especially following a screening-based diagnosis of type 2 diabetes. However, the 
exploratory, cross-sectional study design and the small sample size did not provide 
enough evidence for a well-defined explanation of our findings. For example, it 
remains unclear why a diagnosis resulting from screening appears to be more 
distressing for partners than that for patients. Additional qualitative research may 
provide further insights.
 In patients with poorly controlled type 2 diabetes, a psychological family-based 
intervention targeting negative or inaccurate illness perceptions recently reported 
improvements both in glucose control and in beliefs regarding diabetes, well being, 
diet, exercise and family support.25 A similar approach may be useful in the treatment 
of patients with diabetes detected by screening and further study is needed on 
the effects of interventions that target illness perceptions in patients and their 
partners following a screening-based diagnosis. Future studies should be larger, 
prospective in design and show a greater focus on changes in illness perceptions 
in the first years after diagnosis.
 In conclusion, the illness perceptions of partners are the most influenced by 
the route to diagnosis of type 2 diabetes. Professionals involved in diabetes education 
and treatment should focus on and target the illness perceptions of partners, especially 
where screening is concerned. The Brief IPQ is a simple and effective tool with 
which to investigate these illness perceptions in daily practice.
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Appendix 1   Effect of screening on Brief IPQ scores, compared with clinical 
diagnosis, by age group
Patients Partners
Brief IPQ item
<60 years
β  (95% CI)a
≥60 years
β  (95% CI)a
<60 years
β  (95% CI)a
≥60 years
β  (95% CI)a
1.  Consequences for  
own life
-2.01 
(-4.00 to -0.02)b
0.64 
(-1.49 to 2.77)
2.13 
(0.20 to 4.05)b
0.70 
(-1.71 to 3.10)
2.  Length of time  
diabetes will last
-0.27 
(-1.63 to 1.10)
1.18 
(-1.05 to 3.40)
-1.67 
(-3.28 to -0.05)b
-0.46 
(-1.92 to 0.99)
3.  Patient’s ability to control 
his/her diabetes
0.82 
(-1.24 to 2.89)
0.23 
(-1.74 to 2.20)
2.09 
(0.51 to 3.68)b
1.14 
(-0.42 to 2.70)
4.  Belief in effect of 
treatment
0.23 
(-0.98 to 1.45)
1.40 
(-0.40 to 3.20)
-0.48 
(-1.96 to 1.01)
-0.10 
(-1.59 to 1.78)
5.  Symptoms experienced 
by the patient
-1.79 
(-3.89 to 0.32)
-0.25 
(-2.38 to 1.88)
3.05 
(1.41 to 4.70)b
0.60 
(-1.40 to 2.59)
6.  Concern about  
patient’s diabetes
-1.61 
(-3.75 to 0.53)
0.65 
(-1.49 to 2.79)
1.32 
(-0.37 to 3.02)
2.32 
(-0.14 to 4.78)
7.  Understanding of 
patient’s diabetes
-0.03 
(-1.60 to 1.54)
0.22 
(-1.64 to 2.09)
0.04 
(-1.44 to 1.53)
1.19 
(-0.03 to 2.42)
8.  Emotional impact, e.g. 
anger, fear, depression
-1.37 
(-3.61 to 0.86)
0.95 
(-1.25 to 3.15)
1.85 
(0.12 to 3.57)b
0.58 
(-2.05 to 3.20)
a Adjusted for sex, educational level, duration of diabetes, duration of marriage and insulin use.
b Significant (P <0.05) relative to reference category (=clinical diagnosis group).
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Appendix 2   Effect of screening on Brief IPQ scores, compared with clinical 
diagnosis, by time since diagnosis
Patients Partners
Brief IPQ item
≤6 months
β  (95% CI)a
>6 months
β  (95% CI)a
≤6 months
β  (95% CI)a
>6 months
β  (95% CI)a
1.  Consequences for  
own life
-0.45 
(-3.00 to 2.10)
-0.75 
(-2.50 to 0.99)
1.53 
(-1.54 to 4.61)
1.59 
(-0.22 to 3.41)
2.  Length of time  
diabetes will last
0.99 
(-2.98 to 4.96)
-0.08 
(-0.66 to 2.25)
-0.44 
(-2.88 to 2.00)
-1.46 
(-2.70 to -0.22)b
3.  Patient’s ability to control 
his/her diabetes
-0.86 
(-4.42 to 2.70)
0.80 
(-1.74 to 2.20)
0.53 
(-0.95 to 2.00)
1.73 
(0.34 to 3.12)b
4.  Belief in effect of 
treatment
1.59 
(-0.79 to 3.96)
0.09 
(-1.13 to 1.31)
-1.41 
(-3.85 to 1.03)
0.15 
(-1.06 to 1.35)
5.  Symptoms experienced 
by the patient
-0.42 
(-3.62 to 2.78)
-1.38 
(-3.08 to 0.32)
3.01 
(-0.18 to 6.20)
1.83 
(0.30 to 3.36)b
6.  Concern about  
patient’s diabetes
0.51 
(-2.79 to 3.82)
-1.10 
(-2.86 to 0.66)
0.15 
(-3.39 to 3.69)
2.00 
(0.38 to 3.62)b
7.  Understanding of 
patient’s diabetes
-0.08 
(-2.45 to 2.30)
0.28 
(-1.10 to 1.67)
1.14 
(-0.24 to 2.51)
0.43 
(-0.76 to 1.62)
8.  Emotional impact, e.g. 
anger, fear, depression
0.06 
(-3.27 to 3.39)
-0.45 
(-2.20 to 1.31)
-0.52 
(-4.15 to 3.10)
1.58 
(-0.13 to 3.29)
a Adjusted for age, sex, educational level, duration of marriage and insulin use.
b Significant (P <0.05) relative to reference category (=clinical diagnosis group).
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Abstract 
Purpose Screening guidelines for type 2 diabetes recommend targeting high-risk 
individuals. Our objective was to assess whether diagnosis of type 2 diabetes based 
on opportunistic targeted screening results in lower vascular event rates when 
compared with diagnosis on the basis of clinical signs or symptoms.
Methods In a prospective, nonrandomized, observational study, we enrolled patients 
aged 45 to 75 years from 10 family practices in the Netherlands with a new 
diagnosis of type 2 diabetes, detected either by (1) opportunistic targeted screening 
(n = 359) or (2) clinical signs or symptoms (n = 206). Patients in both groups received 
the same guideline-concordant diabetes care. The main group outcome measure 
was a composite of death from cardiovascular disease (CVD), nonfatal myocardial 
infarction, and nonfatal stroke.
Results Baseline vascular disease was more prevalent in the opportunistic targeted 
screening group, mainly ischemic heart disease (12.3% vs 3.9%, P = 0.001) and 
nephropathy (16.9% vs 7.1%, P = 0.002). After a mean follow-up of 7.7 years (SD = 2.4 
years) and 7.1 years (SD = 2.7 years) years for the opportunistic targeted screening 
and clinical diagnosis groups, respectively, composite primary event rates did not 
differ significantly between the 2 groups (9.5% vs 10.2%, P = 0.78; adjusted hazard 
ratio 0.67, 95% confidence interval, 0.36-1.25; P = 0.21). There were also no significant 
differences in the separate event rates of deaths from CVD, nonfatal myocardial 
infarction, and nonfatal strokes.
Conclusions Opportunistic targeted screening for type 2 diabetes detected patients 
with higher CVD morbidity at baseline when compared with clinical diagnosis 
but showed similar CVD mortality and major CVD morbidity after 7.7 years. 
Opportunistic targeted screening and guided care appears to improve vascular 
outcomes in type 2 diabetes in primary care. 
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Introduction
Targeting screening for type 2 diabetes to high-risk individuals is recommended 
for the prevention of vascular complications.1 The justification for the promotion of 
screening is that patients with type 2 diabetes are already at risk for developing 
microvascular complications before clinical diagnosis2 and have a twofold higher 
risk of cardiovascular disease and mortality.3 The worldwide prevalence of type 2 
diabetes is expected to keep rising in the next decade, dramatically increasing the 
burden of disease and health care costs.4,5
 Glycemic control and cardiovascular risk management (mainly treatment of 
hypertension and hypercholesterolemia) decrease vascular disease and mortality 
in patients with type 2 diabetes.6,7 It is currently uncertain, however, whether 
treatment of patients with type 2 diabetes detected through screening results in 
lower vascular event rates when compared with treatment of patients diagnosed 
by clinical signs or symptoms.6 
 To address this issue, we undertook a study that builds on a type 2 diabetes-
screening program performed by the Diabscreen study, in which diabetes screening 
was conducted during regular primary care in the Netherlands. The Diabscreen 
study reported a fair yield of opportunistic screening, targeting patients at high 
risk for undiagnosed type 2 diabetes who visited their family physician.8 After 
evaluation, the program was implemented in daily practice. Because of the 
continuous nature of the primary care setting of the program, we are now able to 
report a follow-up of up to 10 years after screening. 
 We compared outcomes in patients with type 2 diabetes that had been diagnosed 
by opportunistic targeted screening with outcomes of patients given a diagnosis 
after displaying diabetes signs or symptoms during the same period and in the 
same family practices. All patients had received the same guideline-concordant 
diabetes care after diagnosis, ie, the same glycemic control and cardiovascular risk 
management.9 
 Our main aim was to assess whether opportunistic targeted screening, compared 
with clinical diagnosis, would beneficially affect the risk of death from cardio-
vascular disease, myocardial infarction and stroke.
Methods
Participants and setting
For the current Diabscreen study follow-up, data were available from 10 family 
practices in the Netherlands, all taking part in the Nijmegen Monitoring Project 
(NMP).10,11 The NMP is a practice-based research network of the Radboud University 
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Nijmegen Medical Centre, with an audit-enhanced monitoring system for chronic 
diseases such as type 2 diabetes. Despite this academic alliance, all participants 
are standard community family practices. 
 Every individual in the Netherlands is registered with a family physician, 
and this registration is usually maintained over many years. Type 2 diabetes is 
commonly treated in primary care, and patients may consult a specialist only 
upon referral by the family physician.
 We included data from all patients, aged 45 to 75 years, with newly diagnosed 
type 2 diabetes who were enrolled in the monitoring system by their family 
physician between 1998 and 2005. For the purposes of this study, patients were not 
randomized into a subgroup but were selected by the detection method of their 
diabetes, as recorded in the NMP database: (1) type 2 diabetes detected by 
opportunistic targeted screening; or (2) clinically diagnosed type 2 diabetes based 
on signs or symptoms. These 2 groups are described in detail.
Type 2 diabetes by opportunistic targeted screening
The opportunistic targeted screening procedure was based on the Diabscreen 
study, and some of the current data were derived from that study.8 In brief, we 
considered patients to be at high risk for undiagnosed type 2 diabetes if they had 
1 or more of the following diabetes risk factors, derived from the American 
Diabetes Association (ADA) recommendations for screening for type 2 diabetes1: a 
family history of diabetes (defined as diabetes in a parent, brother, sister, or a 
combination thereof); a history of cardiovascular disease (heart failure, ischemic 
heart disease, myocardial infarction, transient cerebral ischemia, stroke, or 
peripheral arterial disease); obesity (body mass index [BMI] >27 kg/m2); hypertension 
(blood pressure ≥140/90 mm Hg or taking antihypertensive agents); hypercholes-
terolemia (total cholesterol >5.0 mmol/L [>193 mg/dL] or taking a lipid-lowering 
agent); or a history of gestational diabetes mellitus.1,9  
 High-risk patients were labeled as such in the electronic medical record. When 
visiting their family practice for a regular care consultation, high-risk patients 
were invited for screening using fasting plasma glucose testing. Screening was 
accepted in 90% of cases.12 Diagnosis of type 2 diabetes was based on international 
criteria, requiring two fasting plasma glucose measurements on 2 separate days, 
both with a value ≥7.0 mmol/L (≥126 mg/dl).13 
Type 2 diabetes by clinical diagnosis
Patients with clinically diagnosed type 2 diabetes had signs or symptoms of diabetes 
during a practice consultation. If they had classic symptoms of hyperglycemia 
(polyuria and polydipsia), a single, random, plasma glucose measurement of ≥11.1 
mmol/L (≥200 mg/dL) was sufficient for diagnosis. When they had milder symptoms 
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(eg, fatigue, frequent infections, blurred vision), 2 fasting plasma glucose samples, 
on separate days and both ≥7.0 mmol/L (≥126 mg/dl), were required.13
Diabetes treatment
Patients in both study groups received the same standard of diabetes care and 
were treated during routine care consultations by their own family physician and 
practice nurses. Diabetes care was in line with the Dutch family practice guidelines 
for type 2 diabetes:9 recorded on intake and then yearly are family history, smoking 
status, and comorbidities; a physical examination; an ophthalmologic examination 
(fundoscopy or fundus photography); laboratory testing for fasting blood glucose, 
hemoglobin A
1c
, lipids, plasma creatinine, and albuminuria; and education and 
lifestyle advice. 
 Three times a year patients have weight and blood pressure measured, fasting 
blood glucose and hemoglobin A
1c
 tested if on insulin; and education and lifestyle 
advice. Glycemic control is undertaken to reduce hemoglobin A
1c
 to less than 53 
mmol/mol (<7.0%), using a stepwise approach with metformin as a first-choice 
agent when diet is insufficient; a sulphonylurea derivative or insulin is added, if 
necessary. 
 For cardiovascular risk, the target systolic blood pressure is less than 140 mm 
Hg. A statin is recommended unless untreated low-density lipoprotein cholesterol 
is less than 2.5 mmol/L (<160 mg/dL) or the absolute 10-year mortality risk is less 
than 5%. An angiotensin-converting enzyme inhibitor is recommended for micro-
albuminuria even with normal blood pressure, and a platelet aggregation inhibitor 
is indicated for secondary prevention only.
Definition of outcomes
All data were collected from the NMP electronic database. We used all clinical 
information available up to the end of 2009. The primary group outcome during 
follow-up was the composite of death from cardiovascular disease (CVD), nonfatal 
myocardial infarction, and nonfatal stroke. Secondary outcomes included micro- 
vascular complications (diabetic retinopathy, neuropathy, and nephropathy), any 
first CVD event (nonfatal myocardial infarction, nonfatal stroke, heart failure, 
ischemic heart disease, transient cerebral ischemia, or peripheral arterial disease), 
all-cause death, and non-CVD death. Retinopathy was diagnosed with funduscopy 
or fundus photography by an ophthalmologist who reported the result to the 
family physician. Neuropathy was diagnosed by the family physician by physical 
examination in cases showing loss of monofilament sensation in the toes. Nephropathy 
was defined as a glomerular filtration rate <60 mL/min/1.73 m2, estimated by the 
Modification of Diet in Renal Disease Study equation.14
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Statistical analysis
We analyzed participant characteristics at baseline and at last follow-up visit using 
the Pearson χ2 or Fisher exact test for categorical data and the Student t test for 
means where appropriate. The main process and outcome variables of care during 
follow-up were similarly analyzed.
 To compare the primary and secondary outcomes between the 2 study groups, 
we calculated the incidences of the events and applied the Pearson χ2 or Fisher 
exact test for statistical analysis. 
 In Cox regression models, hazard ratios for the outcomes with their 95% 
confidence intervals and P values were calculated. Time to event was defined as the 
time between date of diagnosis and date of cardiovascular event or death. For micro- 
vascular outcomes, the date of event was the date of diagnosis during follow-up. 
Patients were followed until death, loss to follow-up, or end of study (December 31, 
2009). Hazard ratios were unadjusted and adjusted for 6 baseline variables: age, 
sex, CVD, fasting plasma glucose, systolic blood pressure, and plasma creatinine. 
 We conducted all analyses in SPSS 16.0 for Windows (SPSS Inc). All analyses 
were 2-sided, and we considered a P value <0.05 to be significant.
Results
Opportunistic targeted screening detected type 2 diabetes in 359 patients. A clinical 
diagnosis of type 2 diabetes based on signs or symptoms was found in 206 patients 
(Table 1). Patients with clinically diagnosed type 2 diabetes were more likely to be 
men and were generally younger than patients with diabetes detected by screening. 
 At baseline, the prevalence of macrovascular disease was significantly higher 
in the opportunistic targeted screening group, which could be primarily explained 
by ischemic heart disease. Prevalence of diabetic retinopathy and neuropathy 
were similar, but nephropathy was more commonly found with opportunistic 
targeted screening. Mean systolic blood pressure and plasma creatinine were also 
significantly higher in the screening group. As expected, fasting plasma glucose 
and hemoglobin A
1c
 levels were significantly elevated in patients with clinically 
diagnosed diabetes. Other characteristics were similar at baseline. 
Follow-up
Mean systolic blood pressure and plasma creatinine no longer differed between 
the opportunistic targeted screening and clinical diagnosis groups after a mean 
follow-up of 7.7 years (SD [standard deviation] = 2.4 years) and 7.1 years (SD = 2.7 
years), respectively (Table 1). Glucose and cholesterol values had improved and 
smoking had decreased in both groups. 
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Process and outcome variables of care
Processes of care were comparable between both study groups after follow-up 
(Table 2). With regard to outcome variables, we found significantly better glycemic 
control among patients from the opportunistic targeted screening group and less 
frequent insulin treatment, but a higher use of antihypertensive medications. 
Other outcomes of care did not differ significantly from those of the clinical 
diagnosis group.   
Primary outcomes
The composite primary event rates during follow-up did not differ significantly 
between the opportunistic targeted screening and clinical diagnosis groups (9.5% 
vs 10.2%, P = 0.78; adjusted hazard ratio [HR] = 0.67, 95% CI, 0.36-1.25; P = 0.21; Table 
3). The hazard curves, however, show a more steeply increasing risk for a major 
macrovascular event in patients with clinically diagnosed diabetes (Figure 1).
Table 2   Main process and outcome variables of care, at last follow-up for 
opportunistic targeted screening (n = 359) and clinical diagnosis (n = 206) 
groups
Variable
Opportunistic  
targeted screening
No. (%)
Clinical 
diagnosis
No. (%) P
Process of care
HbA1c recorded 345 (96.1) 196 (95.1) 0.59
Systolic blood pressure recorded 349 (97.2) 197 (95.6) 0.32
LDL Cholesterol recorded 332 (92.5) 182 (88.3) 0.10
Eye examination recorded 344 (95.8) 189 (91.7) 0.04
Foot examination recorded 348 (96.9) 192 (93.2) 0.04
Outcome of care
HbA1c <53 mmol/mol (7.0%) 220 (63.8) 99 (50.5) 0.003
Systolic blood pressure <140 mm Hg 126 (36.1) 69 (35.0) 0.80
LDL cholesterol <2.5 mmol/l 159 (47.9) 81 (44.5) 0.46
Glucose-lowering treatment
Diet only 96 (26.7) 34 (16.5) 0.01
Oral agent(s) 231 (64.3) 147 (71.4) 0.09
Insulin 19 (5.3) 26 (12.6) 0.002
Anti-hypertensive agent(s) 228 (71.2) 90 (52.3) <0.001
Lipid-lowering agent(s) 216 (67.7) 109 (63.7) 0.38
HbA1c = hemoglobin A1c; LDL = low-density lipoprotein.
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Lower incidences and risk for nonfatal myocardial infarction and for nonfatal 
stroke were observed in the opportunistic targeted screening group, whereas risk 
for CVD death was higher. Because of the small numbers and a large confidence 
interval, the differences for CVD death were not statistically significant.
Secondary outcomes
Microvascular event rates were also not significantly different between the study 
groups (Table 3), although incidence and risk for diabetic retinopathy were lower 
after opportunistic targeted screening (1.5% vs 3.9%; P = 0.08; adjusted HR = 0.75, 
95% CI, 0.19-3.08; P = 0.69).
 Risk for any first CVD event did not differ significantly between the groups 
(Table 3). Lower incidences and risk were observed in the opportunistic targeted 
screening group for ischemic heart disease, whereas they were higher for heart 
failure, transient cerebral ischemia, and peripheral arterial disease, but these 
differences were not statistically significant or the 95% confidence intervals were 
large (data not shown). 
Figure 1   Cumulative hazard of primary outcome following diagnosis of  
type 2 diabetes by opportunistic targeted screening, compared with 
clinical diagnosis
CVD = cardiovascular disease; HR = hazard ratio.
Notes: Cumulative hazard of death from CVD, nonfatal myocardial infarction, or nonfatal stroke, adjusted for 
age, sex, and the following baseline characteristics: CVD, systolic blood pressure, fasting plasma glucose, and 
plasma creatinine.
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All-cause death rates did not differ significantly (8.6% vs 10.7%; P = 0.42; adjusted 
HR =  0.60, 95% CI, 0.31-1.13; P = .12), in contrast to non-CVD death (4.2% vs 8.7%; 
P = 0.03; adjusted HR = 0.33, 95% CI, 0.15-0.71; P = 0.01; Table 3). We observed more 
deaths caused by infections or pulmonary disease (2.2% vs 1.5%) in the opportunistic 
targeted screening group but fewer deaths that were due to cancer (1.9% vs 7.3%). 
No specific type of cancer could explain the higher prevalence in the clinical 
diagnosis group (data not shown).
Discussion
This study is the first to compare patients from the same population with type 2 
diabetes detected by either opportunistic targeted screening or by clinical signs or 
symptoms and observed for long-term vascular outcomes. 
 For patients with type 2 diabetes detected by opportunistic targeted screening 
who had higher CVD morbidity at baseline, in particular ischemic heart disease 
and hypertension-related nephropathy, after up to 10 years follow-up, major 
macrovascular event rates did not significantly differ between the 2 groups. 
Secondary vascular event rates were also not significantly different between 
groups, although the opportunistic targeted screening group did show a lower 
risk for diabetic retinopathy than the clinical diagnosis group.
Differences at diagnosis between patients with type 2 diabetes detected by 
screening and clinically were described earlier in the Hoorn Screening Study,15 a 
targeted diabetes screening study in the Netherlands. Our data confirmed the 
findings of the Hoorn Screening Study and showed that glucose levels were higher 
among patients with signs or symptoms at diagnosis, whereas retinopathy and 
neuropathy were equally prevalent in the 2 groups. Additionally, these authors 
already noted strikingly prevalent macrovascular complications in patients with 
diabetes detected by screening.16
 The major strength of our study was its particular setting. Although all NMP 
practices are affiliated academically with the Radboud University Nijmegen 
Medical Centre, they are normal community practices with a population 
representative of the general Dutch population and a diabetes prevalence equal to 
that anywhere in the Netherlands.10,17 That the Dutch system of primary health 
care provides for universal access and continuity of patient registration enabled us 
to collect and present follow-up data from daily practice. 
 The effectiveness of screening for type 2 diabetes should preferably be 
investigated in a randomized controlled trial.18 In the current absence of such 
trials and with limited evidence found in recent case-control, cross-sectional, and 
modeling studies,6 we believe that an observational study can provide important 
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new data. Because we could show that patients in both study groups received the 
same level of diabetes care,9 we were able to investigate outcomes related to time of 
diagnosis and early treatment. 
 Overall, we found lower vascular event rates than expected in both the 
opportunistic targeted screening group and the clinical diagnosis group. This 
finding might reflect the impact of the guideline-concordant diabetes care in the 
practices, which includes cardiovascular risk management. Diabetes treatment 
had been successful in reducing blood pressure, smoking, and blood glucose and 
lipid levels in both groups.
We showed that the hazard curve of the primary outcome was higher for clinically 
diagnosed diabetes than for opportunistic targeted screening, which might be 
explained by lead-time bias: the longer interval between diagnosis and development 
of complications in patients detected by opportunistic targeted screening might 
be due to earlier detection in the natural history of the disease, instead of earlier 
treatment.19 The lower glucose levels at diagnosis and lower risk for retinopathy 
for patients with diabetes detected by screening suggests that screening detects 
patients at an earlier stage of disease.2 Patients with diabetes detected by screening 
also tend to show milder disease and slower progression, with better clinical 
outcomes after follow-up (length-time bias).19 Although we screened patients in a 
high-risk population who had a higher initial prevalence of ischemic heart disease, 
nephropathy and hypertension than patients in the clinical diagnosis group, 
vascular outcomes were similar between the groups upon follow-up. Even adjusted 
hazard ratios were not significantly different between groups. The opportunistic 
targeted screening group may have developed diabetes complications caused by 
longer exposure to hyperglycemia as a result of a slower progression. 
 A final possibility is that patients who volunteer for screening programs are 
more health conscious and therefore more likely to have a better disease outcome 
even without screening (selection bias).19 The initiation of screening during routine 
care, the targeting of patients with diabetes risk factors, and the high response 
rate of 90%,8 all suggest that selection bias did not play a major role in our study. 
As previously stated, however, patients with clinically diagnosed diabetes were 
more often men and were generally younger than patients with diabetes detected 
by opportunistic targeted screening. This difference may have been because only 
patients visiting the family practice were invited for screening, and younger men 
might be more likely to postpone a primary care consultation. We adjusted data 
analyses for age and sex to account for this possible bias.
 A selection bias that is due to a selective allocation to a group or treatment by 
the patient’s family physician is also unlikely, because patients were not 
randomized into a group, and although detection method was not blinded, it was 
recorded in the database for analysis purposes only. Patients from both study 
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groups received the same guided treatment during normal care from their own 
family physician, independent of the detection method. 
 A possible limitation may have been the diagnosis of patients with type 2 
diabetes by the fasting plasma glucose test rather than the oral glucose tolerance 
test. The oral glucose tolerance test consists of a fasting plasma glucose test and 
2-hour plasma glucose value and is considered to be the reference standard test in 
the diagnosis of diabetes. The fasting plasma glucose test is more user-friendly, 
however, faster to perform, more convenient and acceptable to patients, and less 
expensive. The recent American Diabetes Association recommendation to use 
hemoglobin A
1c
 for screening was still under debate at the time of our study.1,20 
Although later rectified, there was a large amount of data missing for hemoglobin 
A
1c
 at baseline, because hemoglobin A
1c
 was not yet registered in the database at 
the beginning of the study in 1998. The missing hemoglobin A
1c
 values were 
comparable between groups, reflecting similar care, and the outcome was in line 
with the mean fasting plasma glucose values at baseline.
 With the exception of smoking, we were not able to investigate potential 
differences in lifestyle between groups, such as exercise or diet, because these data 
were not collected in the NMP database. Lifestyle advice is, however, an important 
part of the guided care in the practices.9
 We have shown that within the first decade after diagnosis, in contrast to our 
expectations, opportunistic targeted screening for type 2 diabetes resulted in 
similarly low macrovascular event rates compared with diabetes diagnosed on the 
basis of signs or symptoms. This central finding of our study might be taken as an 
argument against screening. Even so, our finding that higher CVD morbidity at 
baseline did not significantly increase vascular event rates after screening argues 
in favor of opportunistic targeted screening. We also showed that opportunistic 
targeted screening identified patients in an earlier stage of diabetes and that these 
patients had a lower risk for retinopathy during follow-up. Furthermore, we found 
a trend toward a higher risk for a major macrovascular event in clinically 
diagnosed type 2 diabetes, and significant differences may yet become apparent 
over time.21 
 We have no explanation for the higher risk for non-CVD death (mainly caused 
by various types of cancer) in the group with clinically diagnosed diabetes. 
Although type 2 diabetes has been associated with an increased cancer risk, 
hyperglycemia could not be causally linked to this risk.22 
 Even though the overall statistical power of the study may not have been 
sufficient to detect small differences between groups, our observational study 
based on daily care did show some interesting results and trends. Further research 
is needed to investigate our findings in a larger setting and with a longer follow-up.
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Comment on: Vascular outcomes in patients with screen-detected 
or clinically diagnosed type 2 diabetes: Diabscreen study follow-up 
Rebecca K. Simmons, Simon J. Griffin
Annals of Family Medicine 2013; eLetter February 4
We congratulate the authors on an interesting study, which adds to the limited 
literature on screening and early treatment for diabetes. As the authors note, 
screening for type 2 diabetes identifies individuals at high cardiovascular risk1 
who might benefit from early intervention. However, while it is tempting to 
speculate that finding and treating individuals earlier in the disease trajectory 
will lead to improved vascular outcomes for people with type 2 diabetes in 
primary care, we do not share the authors' confidence that this can be concluded 
from the data that they report. The study design does not allow for this research 
question to be answered without recruiting a group of individuals who 
meet the criteria for opportunistic screening but who do not receive it and are 
subsequently followed up for vascular outcomes. As the authors note, their 
observational data are subject to both lead and length time bias, which make 
the results challenging to interpret. 
 Examination of Table 1 shows that there were baseline differences in 
nephropathy and BMI, which were not adjusted for in Cox regression models. 
Further, it may have been useful to adjust for HbA1c, rather than fasting blood 
glucose, which better predicts long-term CVD outcomes. Data from Table 2 
suggest that screen-detected and clinically diagnosed diabetes patients did not 
receive the same level of treatment. Larger proportions of the screen-detected 
individuals received diet and anti-hypertensive treatment, while higher 
numbers of clinically diagnosed patients received oral agents and insulin. 
Again, these differences make it challenging to directly compare the vascular 
experience of the two groups. It would be interesting to know how information 
on vascular outcomes was collected in this study, and how these were assessed 
or adjudicated. Some attempt to quantify or discuss the potential harms of 
screening would also have strengthened the author's assertion about the net 
benefits of screening.2
 The only way to avoid lead and length time bias and to assess the net benefit 
of screening and early treatment is to conduct an RCT. Intensive treatment in 
the lead time between early detection and clinical diagnosis was associated 
with a non-significant 17% relative risk reduction in a cardiovascular composite 
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outcome among screen-detected individuals in the ADDITION-Europe trial 
after five years of follow-up.3 Furthermore, examination of the impact of 
invitation to screening on mortality at the population level showed that there 
was no significant difference in all-cause, cardiovascular, or diabetes-related 
mortality between screening and control groups after ten years of follow-up.4 
Thus, while early detection and treatment might improve outcomes for the 
minority with detectable disease, these results constitute the strongest evidence to 
date that the benefits of population screening for diabetes might have been 
overestimated. 
 Given the current uncertainties concerning the cost effectiveness of 
screening and early treatment for diabetes, we agree with Klein Woolthuis and 
colleagues that it is probably most efficient to restrict opportunistic screening 
to those known to be at highest risk based on readily available information. 
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eLetter
We thank Simmons and Griffin for congratulating us on our recent observational 
study which showed that a diabetes diagnosis via opportunistic targeted screening 
or via clinical signs and symptoms gave similar rates of illness and death from 
cardiovascular disease over a 7-year period,1 and we appreciate their comments.
 We agree that the effectiveness of diabetes screening should preferably be 
estimated by an RCT, so therefore we highly respect their recent work.2,3 Strictly 
speaking, as Simmons and Griffin rightly state, an RCT should contain a control 
group of individuals who meet the criteria for screening but who do not receive it. 
While guidelines nowadays recommend targeted screening in high-risk individuals,4 
and with people at risk being more aware than ever of the need of glucose testing, 
we do not think it would be possible to rule out any kind of (opportunistic) screening in 
control groups. Unfortunately, it appears that Simmons and colleagues did not have 
access to this information in their no-screening control group.3
 Our observational study was suitable for daily care and could therefore be 
implemented in other practices without much effort. Since patients in both study 
groups received the same guided treatment during normal care from their own 
family physician, we were able to investigate outcomes related to time of diagnosis 
and early treatment.
 Indeed, lead- and length-time bias could not be ruled out, but were not likely to 
play a major role in our study. The lower glucose levels and prevalence of retinopathy 
at diagnosis showed that screening detected diabetes at an earlier stage of disease, 
and recently it has been shown that screening may bring forward the diagnosis of 
diabetes by only 3 years.5 Also, our study outcomes were not significantly different 
between the study groups, making our findings comparable with those from the 
recent trial by Simmons and colleagues. 
 Simmons and Griffin formulated some specific critiques. Regarding Table 1, 
we already adjusted for plasma creatinine, and BMI was not significantly different 
between the two groups. We agree that it might have been useful to adjust for 
HbA
1c
, but unfortunately the amount of missing values at baseline was high as this 
test was fairly new at the time. The level of treatment between groups was similar 
with respect to process of care. Medication differences reflected earlier treatment 
in the screening group, and showed that it was easier to control hyperglycemia in 
this group with much less effort, which may be an argument in favor of screening. 
Vascular outcomes were retrieved from the family physicians’ electronic medical 
record (EMR), in which all diagnoses of disease and death are reliably ICPC coded, 
as part of our academic registration network.6,7 And recently we have reported that 
the route to diagnosis of type 2 diabetes has a greater impact on the illness 
perceptions of partners than of patients.8 
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 Together with a high response rate of 90% and a fair yield,9 we showed that 
with an opportunistic targeted screening program like ours, using the EMR for 
risk assessment prior to glucose testing, diabetes screening in primary care can be 
performed systematically and continuously, as part of cardiovascular risk 
management. 
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In retrospect
Clinical guidelines recommend screening for type 2 diabetes in high-risk groups, 
assuming that this will prevent vascular complications.1-4 However, no direct 
supportive evidence exists, nor is there a standardized screening approach. 
 This thesis addressed several aspects of opportunistic targeted screening for 
type 2 diabetes in primary care, which entails screening individuals at high risk 
for undiagnosed type 2 diabetes during regular care consultations.
 The studies described in this thesis were part of or used data from the Diabscreen 
study, an opportunistic targeted screening programme for type 2 diabetes in 
patients aged 45 to 75 years in general practices in the Netherlands, using the general 
practitioner’s (GP) electronic medical record (EMR) for risk assessment before 
glucose testing. The GP’s EMR might be an attractive, inviting tool for a systematic 
and repeated identification of high-risk patients in opportunistic screening. 
 The feasibility and yield of opportunistic targeted screening in primary care 
were evaluated. Moreover, it was investigated how the route to diagnosis of type 2 
diabetes – through screening or by clinical signs or symptoms – affects illness 
perceptions in patients and their partners. And finally, the effectiveness on long-term 
vascular outcomes of screening, compared with clinical diagnosis, was assessed.    
 This final chapter summarizes and reflects on the main findings of this thesis. 
The main methodological issues of the studies and the ongoing screening debate 
will be discussed. The chapter ends with clinical implications, recommendations 
for future research, and five key messages.
Main findings
Feasibility and yield 
The Diabscreen study has shown that the medical data stored in the GP’s EMR were 
helpful but in themselves incomplete in identifying individuals at high risk for 
undiagnosed type 2 diabetes (Chapter 2). In particular, obesity and a family history 
of diabetes, both risk factors that may change over time, were poorly registered. 
This made additional risk assessment during consultation required to come to a 
reliable valuing of individuals’ risk status. After updating the EMR for missing 
data, though, it was feasible to use the acquired risk status to opportunistically 
initiate screening. In total, about two-thirds of the study population were at high 
risk, most of them having hypertension or cardiovascular disease.
 The stepwise glucose testing protocol of the Diabscreen study was well applicable 
in general practice (Chapter 3). It included a first capillary fasting plasma glucose 
(FPG) measurement from a portable blood glucose meter and, if indicated by the 
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result (>6.0 mmol/l [110 mg/dl]), a second one, and if indicated by that result (>6.0 
mmol/l with at least one of the two measurements being ≥7.0 mmol/l [126 mg/dl]), 
a venous FPG. Response rates for both capillary measurements were high (about 
90%), and the protocol’s high positive predictive value (81%) resulted in a 
considerable reduction of patients in whom a venous FPG had to be assessed.
 The yield of opportunistic targeted screening among high-risk patients in the 
Diabscreen study was fair, largely because of the stepwise protocol, and much 
higher than in low-risk patients; obesity alone was the best predictor of undiagnosed 
type 2 diabetes (Chapter 4).
 The clinical findings of the Diabscreen study support the conclusion of a 
recent modelling study,5 that the cost-effectiveness of screening for type 2 diabetes 
would be improved if screening was done opportunistically and by risk assessment 
before glucose testing (Chapter 5). 
 It was concluded that opportunistic screening in primary care, as proceeded 
in the Diabscreen study, was feasible. Middle-aged and older adults at high risk, 
especially those with obesity, can be targeted effectively. A well-kept EMR can be 
most helpful for identification of high-risk patients and also in supporting repeated 
screening. With systematic integration of diabetes screening into cardiovascular 
risk management, the number of high-risk patients to be opportunistically 
screened would be considerably reduced.
The partner’s perspective
In a cross-sectional questionnaire study using the Brief Illness Perception Questionnaire 
(Brief IPQ),6 the route to diagnosis of type 2 diabetes had a greater impact on the 
illness perceptions of partners than that of patients (Chapter 6). Partners of patients 
diagnosed through screening perceived greater consequences for their own life, 
had a stronger feeling that their patient-partners had control over their diabetes, 
were more concerned about their partners’ diabetes, and believed that their pa-
tient-partners experienced more diabetes symptoms, compared with partners of 
patients who were diagnosed through clinical signs or symptoms.
 Professionals involved in diabetes education and treatment should focus on 
and target the illness perceptions of partners, especially where screening is 
concerned. The Brief IPQ is a simple and effective tool with which to investigate 
these illness perceptions in daily practice.
Long-term effectiveness
The Diabscreen study follow-up confirmed the findings of earlier screening studies 
that opportunistic targeted screening for type 2 diabetes detects patients with 
higher cardiovascular disease (CVD) morbidity at baseline when compared with 
clinical diagnosis.7,8 Despite this high cardiovascular risk in screen-detected 
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patients, the vascular event rates were low and did not differ significantly between 
the two groups after a mean follow-up of 7.7 years (Chapters 7 and 8). 
 Opportunistic targeted screening and guided care including cardiovascular 
risk management appears to improve long-term vascular outcomes in type 2 
diabetes in primary care.
Methodological considerations
There are several methodological issues regarding screening studies, and many 
have already been addressed in the previous chapters of this thesis. Some important 
strengths and possible limitations are also worth discussing in this section.  
Study setting
The major strength of this thesis was its primary care setting. Although many 
participants of the studies described in this thesis were recruited from general 
practices with an interest in diabetes care, these practices were normal community 
practices with a population and diabetes prevalence rates representative of the 
general Dutch population.9-14 
 In the Diabscreen study, high-risk patients were invited for screening during 
daily routine practice in the patients’ local general practice by their own GP. 
Capillary blood samples were taken by the practice assistants in the patients’ own 
practice, without any further support (eg, from trial nurses). Probably due to these 
factors, patients were highly willing to return in a fasting state for the capillary 
FPG measurement.
 Because the Dutch system of primary healthcare provides for universal access 
and continuity of patient registration, data from the general practice’s EMR could 
be used in a continuous screening programme, as well as in the follow-up study.
Biases in screening
Important biases that are frequently associated with (observational) screening 
studies can confound assessment of screening-test efficacy.15
 In the Diabscreen study follow-up, the hazard curve of the primary outcome 
was higher for clinically diagnosed diabetes than for opportunistic targeted 
screening (Chapter 7). This might be explained by lead-time bias: the longer interval 
between diagnosis and development of complications in patients detected by 
opportunistic targeted screening might be due to earlier detection in the natural 
history of the disease, instead of earlier treatment (Figure 1 A).15 The lower glucose 
levels at diagnosis and lower risk for retinopathy in screen-detected patients 
showed that screening detected patients at an earlier stage of disease.16 
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Figure 1   Lead-time bias (A) and length-time bias (B)
O = time of disease onset; Dx = diagnosis.
Lead time = interval between early diagnosis by screening and usual diagnosis by clinical signs or symptoms.
Lead-time bias = overestimation of survival duration among screen-detected vs clinically diagnosed patients. 
Length-time bias = overestimation of survival duration among screen-detected patients due to relative excess of 
slowly progressing cases.
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 Patients with diabetes detected by screening also tend to show milder disease 
and slower progression, with better clinical outcomes after follow-up (length-time 
bias, Figure 1 B).15 However, although a high-risk population was screened with a 
higher initial prevalence of ischemic heart disease, nephropathy and hypertension 
than in the clinical diagnosis group, vascular outcomes were similar between the 
groups upon follow-up (Chapter 7). Even adjusted hazard ratios were not significantly 
different between groups. The opportunistic targeted screening group may have 
developed diabetes complications caused by longer exposure to hyperglycemia as 
a result of a slower progression.
Furthermore, patients who volunteer for screening programmes are more health 
conscious and therefore more likely to have a better disease outcome even without 
screening (selection bias).15 The initiation of screening during routine care, the 
targeting of patients with diabetes risk factors, and the high response rate of 90% 
(Chapter 4), all suggest that selection bias did not play a significant role in the 
Diabscreen study. However, clinically diagnosed patients were more often men 
and were generally younger than patients detected by opportunistic targeted 
screening. This difference may have been because only patients visiting the 
general practice were invited for screening, and younger men might be more 
likely to postpone a primary care consultation. Data analyses were adjusted for age 
and sex to account for this possible bias (Chapter 7).
 A selection bias due to a selective allocation to a group or treatment by the 
patient’s GP is also unlikely because patients were not randomized into a group 
but selected by the route to diagnosis (Chapters 6 and 7). Patients in both study 
groups (diagnosed by screening or by clinical signs or symptoms) were all treated 
according to the same practice guidelines during usual care. 
 Volunteer or self-selection bias cannot be entirely ruled out, however, because 
response rates were low and some baseline characteristics differed between the 
study groups (Chapter 6). Data analyses were adjusted for these differences to 
account for any possible bias. 
To screen or not to screen: an ongoing debate
Screening for undiagnosed type 2 diabetes is still under debate and there is no 
definite answer yet to the question whether we should screen for type 2 diabetes or 
not.17,18 Those who are opposed to screening suggest that a population approach to 
modifying cardiovascular risk factors would be better.18 Changes to diet or physical 
activity levels will always be advisable for people who are overweight or sedentary, 
whatever their overall diabetes or cardiovascular risk score and whatever their 
glucose result, and focusing on diabetes risk alone ignores the additional benefits 
of weight loss and exercise. A recent modelling study suggests that it may be as 
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effective to treat on the basis of age alone as on the basis of a more complex risk 
assessment including blood pressure and cholesterol levels.19 In England, the 
National Health Service has started the Health Check programme, which offers 
cardiovascular risk assessment including diabetes screening every five years to 
anyone between the ages of 40 and 74 years.20 In the Netherlands, GPs can offer 
individual patients or the practice population from the age of 45 years a 
cardiovascular risk assessment, so-called Preventative Consultation, using a 
validated risk score including diabetes risk factors (eg, BMI and family history of 
type 2 diabetes).21 
 Others believe that screening for diabetes is feasible and cost-effective.17 
Screening followed by lifestyle interventions have been proven to be both effective 
and cost-effective in people with newly detected prediabetes and diabetes.22 A 
recent modelling study concluded that screening is cost-effective when started 
between the ages of 30 and 45 years, with screening repeated every three to five 
years.5 The British National Institute for Health and Clinical Excellence (NICE) has 
published guidance on identification and prevention of type 2 diabetes in people 
at high risk, making practical recommendations on risk identification using self-
assessment risk scores or computer based risk scores in people aged 40 to 75 years 
followed by glucose or Hemoglobin A
1c
 testing.23 The American Diabetes Association 
recommends three-yearly screening for undiagnosed type 2 diabetes in adults of 
any age with a BMI ≥25 and with additional risk factors, or starting at age 45 
without these risk factors.4 And the Dutch general practice guidelines for type 2 
diabetes recommend three-yearly screening for type 2 diabetes in individuals aged 
45 years or older with diabetes or cardiovascular risk factors, or with CVD.2
 Recently, two population-based screening trials in high-risk individuals have 
reported important new findings. Intensive treatment between early detection by 
screening and clinical diagnosis was associated with a non-significant reduction 
in CVD among screen-detected individuals in the ADDITION-Europe trial after five 
years of follow-up.24 The ADDITION-Cambridge trial showed that there was no 
significant difference in mortality between screening and control groups after ten 
years of follow-up.25 
 These finding are comparable to the findings in this thesis (Chapter 7), and 
might be taken as an argument against screening, suggesting that efforts in 
primary prevention among those at high risk for developing diabetes may be more 
important than early detection and treatment of undiagnosed diabetes. 
 On the other hand, it would have been expected that screen-detected patients 
with more pre-existing CVD would subsequently experience more CVD events, but 
they did not, probably because of cardiovascular risk management after diagnosis, 
which argues in favour of opportunistic targeted screening. Furthermore, 
observational follow-up data from the Diabscreen study showed a trend toward an 
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increasingly lower risk for a major CVD event in screen-detected type 2 diabetes, 
and significant differences may yet become apparent over time. 
Clinical implications
The benefits of screening appear to be smaller than expected, but could be 
increased by combining diabetes screening with cardiovascular risk assessment 
and continuous or repeated screening. This asks for a dynamic process, in which 
the interaction between practice and practice population over time is directed at 
pro-actively assessing risk status and acting upon it. 
 In this respect, it is important to come back to the initial finding of the 
incompleteness of the GP’s EMR at the start of the Diabscreen study in terms of 
diabetes risk status. Updating of information of individuals’ health status and 
health risk should be seen as an integral part of pro-active diabetes risk and 
cardiovascular risk management. Individuals’ risk status may change over time, as 
do scientific evidence and professional values of risk factors. The EMR should be a 
reflection of the best available information. 
Future research
Further research is needed to investigate this thesis’ findings in a larger setting 
and with a longer follow-up. The focus should be on long-term outcomes of 
cardiovascular risk management with integrated diabetes screening. Future 
studies should also estimate its cost-effectiveness and limitations. Furthermore, 
data on non-Caucasian individuals and on other less well known diabetes risk 
factors (eg, polycystic ovary syndrome26) may be investigated.
Key messages
The studies presented in this thesis have provided better insight in opportunistic 
targeted screening for type 2 diabetes in primary care. Five key messages can be 
formulated.
1. This thesis shows that opportunistic targeted screening for type 2 diabetes in 
primary care is feasible, and a well-kept electronic medical record with 
up-to-date cardiovascular risk profile can be most helpful for identification of 
high-risk patients and supportive in repeated screening. 
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2. Diabetes screening should be systematically integrated into cardiovascular 
risk management, so that opportunistic screening for type 2 diabetes can 
effectively target middle-aged and older adults with diabetes risk factors, in 
particular obesity. This asks for active management of information on 
individuals’ risk status in the EMR to support screening and identification of 
those to benefit from it. 
3. Professionals involved in diabetes education and treatment should focus on 
and target the illness perceptions of partners, especially where screening is 
concerned. The Brief Illness Perception Questionnaire is a simple and effective 
tool with which to investigate these illness perceptions in daily practice.
4. Opportunistic targeted screening and guided care including cardiovascular 
risk management appears to improve long-term vascular outcomes in type 2 
diabetes in primary care, which is an important argument in favour of 
screening.
5. Future research should investigate long-term outcomes of cardiovascular risk 
management with integrated diabetes screening.
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This thesis addresses several aspects of opportunistic targeted screening for type 2 
diabetes in primary care, which entails screening asymptomatic individuals at 
high risk for undiagnosed type 2 diabetes during regular healthcare consultations.
In Chapter 1 the rationale and objectives of this thesis are described. Clinical guidelines 
recommend screening for undiagnosed type 2 diabetes in high-risk groups, assuming 
that this will prevent vascular complications. However, no direct supportive evidence 
exists, nor is there a standardized screening approach. Opportunistic targeted 
screening using clinical risk factor information from the electronic medical 
record (EMR) may be an efficient and continuous method of detecting undiagnosed 
type 2 diabetes during usual primary healthcare.
 To investigate this screening approach, from the year 2000 to 2001 the Diabscreen 
study had been conducted. This was an opportunistic targeted screening programme 
for type 2 diabetes among patients aged 45-75 years in general practices in the 
Netherlands, using the general practitioner’s (GP) EMR for risk assessment before 
glucose testing.
 The first objective of this thesis was to evaluate the feasibility and yield of 
opportunistic targeted screening for type 2 diabetes in primary care. Secondly, to 
address the family perspective of screening, this thesis aimed to examine how the 
route to diagnosis of type 2 diabetes – through screening or by clinical signs or 
symptoms – affects illness perceptions in families, particularly in patients and 
their partners. The third objective was to assess the effectiveness on long-term 
vascular outcomes of opportunistic targeted screening for type 2 diabetes, 
compared with a clinical diagnosis.
In Chapter 2 the design and results of the first steps of the Diabscreen study are 
described. Using a computerized cross-sectional analysis of diabetes risk factor 
information (diagnoses and medication) for each patient from the practices’ EMR, 
the patient’s risk for undiagnosed diabetes (high or low risk) was marked in the EMR. 
During a usual care consultation in the following year, the EMR reminded the GP to 
verify and, in the case of missing data, complete the patients’ risk profile and to 
invite high-risk patients for a capillary fasting plasma glucose (FPG) measurement. 
 Of the population aged 45-75 years and not already known with diabetes, 28% 
had an EMR-based risk (hypertension, cardiovascular disease, lipid metabolism 
disorders and/or obesity). Additional risk assessment in those without an EMR-based 
risk showed that in 51%, greater than one risk factor was present, mainly family 
history of diabetes (51.2%) and obesity (59%). Ninety per cent of high-risk patients 
returned for the capillary FPG measurement. 
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These findings suggest that with additional risk assessment during consultation, 
the GP’s EMR is valuable in identifying patients at high risk for undiagnosed type 
2 diabetes, and that it is feasible to use this information to initiate screening. 
In Chapter 3 the stepwise glucose testing protocol of the Diabscreen study is 
evaluated. The protocol consisted of two capillary FPG measurements with a 
combination of two cut-off points (6.0 mmol/l and 7.0 mmol/l [110 mg/dl and 126 
mg/dl]), and a venous FPG. All samples were taken in the patients’ own general 
practice, by their own practice assistants. Plasma calibrated portable blood 
glucose meters were used for the capillary measurements. Patients with an initial 
value >6.0 mmol/l were invited for a second capillary FPG on another day. This 
was immediately followed by a venous sample if at least one of the capillary 
measurements was ≥7.0 mmol/l. 
 Fasting capillary and venous glucose values were highly correlated, with the 
latter being systematically higher. With response rates for both capillary 
measurements at about 90% and a positive predictive value for having undiagnosed 
type 2 diabetes of 81% (in 101 out of 125 patients the venous FPG was ≥7.0 mmol/l), 
the protocol was well applicable.
In Chapter 4 the yield of the Diabscreen study was assessed. In addition to high-risk 
patients who were invited during usual care, a random sample of low-risk patients 
was contacted by mail for stepwise fasting glucose testing. 
 Ultimately, the screening yield (percentage of invited patients with undiagnosed 
type 2 diabetes) was much higher in high-risk than in low-risk patients (2.7% versus 
0.4%; number needed to screen 37 versus 233). Obesity was the best predictor of 
undiagnosed type 2 diabetes (odds ratio 3.2).
 The yield of opportunistic targeted screening was fair; obesity alone was the 
best predictor of undiagnosed diabetes. Opportunistic targeted screening for type 
2 diabetes in primary care could target middle-aged and older adults with obesity.
Chapter 5 comments on a recent modelling study about the cost-effectiveness of 
screening for type 2 diabetes. This study concluded that the cost per quality-adjusted 
life-year would be improved if screening was done opportunistically and by risk 
assessment before glucose testing. 
 The clinical findings of the Diabscreen study clearly show that opportunistic 
screening in primary care is feasible. Middle-aged and older adults at high risk, 
especially those with obesity, can be targeted effectively. An EMR can be most 
helpful for identification of high-risk patients and also in supporting repeated 
screening, but this requires universal access and continuity of patient registration.
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Chapter 6 focuses on the partner’s perspective on screening. As most type 2 diabetes 
self-care occurs at home, beliefs or illness perceptions of in particular the partner 
regarding type 2 diabetes play an important role in adaptation to the disease and 
in disease outcome. In this chapter it was investigated how the route to diagnosis 
of type 2 diabetes, through screening or by clinical signs or symptoms, affects the 
illness perceptions of patients and their partners.
 In a cross-sectional study, patients aged 40-75 years from general practices 
with a new diagnosis of type 2 diabetes (≤3 years), detected by either screening or 
clinical signs or symptoms, were enrolled. Patients and their partners each 
completed a postal Brief Illness Perception Questionnaire (Brief IPQ), and up-to-date 
clinical data were obtained from their GP.
 The route to diagnosis did not appear to have a strong influence on patients’ 
illness perceptions, but did influence illness perceptions of their partners. Partners 
of patients diagnosed through screening perceived greater consequences for their 
own life, had a stronger feeling that their patient-partners had control over their 
diabetes, were more concerned about their partners’ diabetes, and believed that 
their patient-partners experienced more diabetes symptoms, compared with 
partners of patients who were diagnosed through clinical symptoms. Professionals 
in diabetes education and treatment should consider these differences in their 
approach to patient care.
In Chapter 7 the Diabscreen study follow-up is described, assessing whether diagnosis of 
type 2 diabetes based on opportunistic targeted screening results in lower vascular 
event rates compared with diagnosis on the basis of clinical signs or symptoms. 
 Opportunistic targeted screening for type 2 diabetes detected patients with 
higher cardiovascular disease (CVD) at baseline when compared with clinical 
diagnosis, mainly ischemic heart disease (12.3% versus 3.9%). But the event rates of 
the primary endpoint (a composite of death from CVD, nonfatal myocardial 
infarction, and nonfatal stroke) were similar after 7.7 years (9.5% versus 10.2%). 
 Opportunistic targeted screening and guided care including cardiovascular 
risk management appears to improve long-term vascular outcomes in type 2 
diabetes in primary care.
Chapter 8 contains the response to a comment on the Diabscreen study follow-up, 
presented in the previous chapter. 
 Together with a high response rate of 90% and a fair yield, it was shown that 
with the Diabscreen study’s opportunistic targeted screening programme, using 
the EMR for risk assessment prior to glucose testing, diabetes screening in primary 
care can be performed systematically and continuously, as part of cardiovascular 
risk management. 
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Finally, in Chapter 9, the main findings of this thesis are summarized and reflected 
on. The main methodological issues of the studies and the ongoing screening 
debate are discussed. The chapter ends with clinical implications, recommendations 
for future research, and five key messages.
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Dit proefschrift richt zich op het opsporen van nog niet ontdekte diabetes type 2 
in de huisartsenpraktijk (primary care) door middel van gerichte, opportunistische 
screening (opportunistic targeted screening). Hierbij worden mensen met een verhoogd 
risico op diabetes maar zonder diabetesklachten of -verschijnselen, tijdens een 
spreekuurbezoek vanwege een andere vraag of klacht, uitgenodigd voor een 
diabetestest, zoals een meting van de bloedsuiker (bloedglucose). 
In Hoofdstuk 1 worden de achtergrond en doelen van dit proefschrift beschreven. 
Diabetes mellitus (‘suikerziekte’), kortweg diabetes genoemd, is een stofwisselings-
ziekte waarbij het lichaam de bloedglucose niet meer in evenwicht kan houden en 
deze te hoog wordt. Hierdoor kan in de loop van de jaren schade ontstaan aan de 
kleine bloedvaten, met als gevolg bijvoorbeeld uitval van de nieren (nefropathie) 
en slechtziendheid (retinopathie), maar ook schade aan de zenuwen (neuropathie) 
met vooral gevoelsstoornissen en risico op wonden aan de voeten. Dit worden 
 microvasculaire complicaties genoemd. Daarnaast hebben mensen met diabetes een 
verhoogd risico op het krijgen van schade aan de grotere bloedvaten en het hart, 
met als gevolg zogenaamde macrovasculaire complicaties – hart- en vaatziekten 
zoals een hartinfarct of herseninfarct – of overlijden. 
 Er zijn verschillende typen diabetes, elk met een verschillende oorzaak en 
meestal ook met een eigen behandeling. Dit proefschrift is gericht op diabetes 
type 2. Negen van de tien mensen met diabetes hebben dit type, waarvan de 
meesten worden behandeld in de huisartsenpraktijk. Diabetes type 2 werd vroeger 
‘ouderdomssuiker’ genoemd, maar tegenwoordig krijgen ook steeds meer jonge 
mensen het. Diabetes type 2 ontstaat doordat er te weinig van het hormoon 
insuline, nodig voor de opname van bloedglucose, in het lichaam aanwezig is. 
Bovendien is het lichaam vaak ongevoeliger voor insuline (insulineresistentie). 
Bij diabetes type 2 kan het jaren duren voordat mensen er klachten van krijgen 
(bijvoorbeeld dorst en vaak plassen). Intussen kunnen er al wel complicaties 
ontstaan. Diabetes type 2 komt steeds meer voor, vooral door vergrijzing en de 
toename van het aantal mensen met overgewicht en obesitas.
 Diabetesrichtlijnen adviseren te screenen op onontdekte diabetes type 2 in 
hoogrisicogroepen, bijvoorbeeld mensen met obesitas (ernstig overgewicht) of 
hoge bloeddruk, omdat vroege behandeling mogelijk complicaties kan voorkomen. 
Hiervoor is echter nog geen bewijs geleverd. Ook is er geen standaard afspraak hoe 
te screenen. Gerichte, opportunistische screening aan de hand van het risicoprofiel 
in een elektronisch patiëntendossier zoals dat van de huisarts (H-EPD genoemd), 
kan een efficiënte manier zijn om nog niet ontdekte diabetes type 2 tijdens gewone 
spreekuurbezoeken op te sporen.
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Om dit wetenschappelijk te onderzoeken, is van 2000 tot 2001 Diabscreen uitgevoerd. 
Deze studie onderzocht het opsporen van nog onontdekte diabetes type 2 onder 
45- tot 75-jarige hoogrisicopatiënten door middel van opportunistische screening 
in Nederlandse huisartsenpraktijken verbonden aan het Universitair Medisch 
Centrum St Radboud Nijmegen (Netwerk Academische Huisartspraktijken Nijmegen 
CMR NMP, kortweg NMP, van de afdeling Eerstelijnsgeneeskunde). Ook praktijken 
van het RegistratieNet Huisartspraktijken (RNH) van het Maastricht Universitair 
Medisch Centrum en enkele praktijken verbonden aan het VU medisch centrum 
Amsterdam deden mee.
 Het eerste doel van dit proefschrift was om de uitvoerbaarheid ( feasibility) en 
effectiviteit op basis van de opbrengst (yield) van opportunistische screening naar 
diabetes type 2, gericht op hoogrisicogroepen in de huisartsenpraktijk, te evalueren. 
Het tweede doel was om te onderzoeken of de manier van opsporen van diabetes 
type 2 – via screening of naar aanleiding van klachten – invloed heeft op de ideeën 
of gedachten over de ziekte bij zowel de patiënt als bij zijn/haar partner, ook wel 
ziektepercepties (illness perceptions) genoemd. Het derde en laatste doel was het vast- 
stellen van de effectiviteit op lange termijn (long-term effectiveness) van opportunistische 
screening onder hoogrisicopatiënten, waarbij na de diagnose diabetes type 2 het 
ontstaan van microvasculaire en macrovasculaire complicaties in de screenings-
groep is vergeleken met het ontstaan daarvan in een groep patiënten met diabetes, 
ontdekt naar aanleiding van klachten.
In Hoofdstuk 2 worden de opzet en resultaten van de eerste stappen van Diabscreen 
beschreven. Op basis van in het H-EPD beschikbare informatie (diagnosen en 
medicatie) werd aan alle 45- tot 75-jarigen in de onderzoekspraktijken een 
risicolabel toegekend: hoog risico (één of meer risicofactoren) of laag risico. 
Geholpen door een geautomatiseerde signalering op het beeldscherm van de 
huisarts, werd gedurende een jaar tijdens gewone spreekuurcontacten dit risico 
door de huisarts gecontroleerd en zo nodig aangepast. Patiënten met een hoog 
risico werden uitgenodigd om via een capillaire meting (vingerprik) de nuchtere 
bloedglucose te laten bepalen.
 Van de populatie 45- tot 75-jarigen zonder al bekende diabetes, had 28% één 
of meer risicofactoren voor onontdekte diabetes in het H-EPD (hoge bloeddruk, 
hart- of vaatziekte, verhoogd cholesterol en/of obesitas). Van de laagrisicopatiënten 
bleek bij navraag tijdens het spreekuur 51% alsnog risicofactoren te hebben, vooral 
diabetes in de familie (ouders, broer en/of zus; 51.2%) en obesitas (59%). De opkomst 
voor de nuchtere bloedglucosemeting was hoog: 90%.
 Het H-EPD bleek goed bruikbaar bij het identificeren van patiënten met een 
hoog risico voor onontdekte diabetes. Als risicoprofielen goed worden bijgehouden 
en aangevuld – vooral bij diabetes in de familie en obesitas – kan met het H-EPD 
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screening naar diabetes tijdens gewone spreekuurcontacten snel en effectief in 
gang worden gezet en regelmatig worden herhaald. 
In Hoofdstuk 3 wordt het volledige stapsgewijze protocol voor bloedglucosemetingen 
in Diabscreen geëvalueerd. Dit bestond uit maximaal twee capillaire metingen met 
een draagbare bloedglucosemeter, zo nodig gevolgd door afname van veneus 
(aderlijk) bloed uit de arm van de patiënt voor een laboratoriummeting. De bloed-
glucosemeters waren, zoals inmiddels standaard bij alle bloedglucosemeters, veneus 
gekalibreerd (afgesteld), waardoor automatisch veneuze waarden werden weer - 
gegeven. Bij een eerste nuchtere bloedglucose hoger dan 6,0 mmol/l, werd de patiënt 
uitgenodigd voor een tweede nuchtere meting op een andere dag. Als de tweede 
bloedglucose ook hoger was dan 6,0 mmol/l én als ten minste één van de twee 
metingen hoger was dan 7,0 mmol/l, werd meteen veneus bloed afgenomen. Alle 
bloedafnamen en alle capillaire metingen werden bij patiënten uitgevoerd in de 
eigen huisartsenpraktijk door een van de eigen praktijkassistentes. Capillaire en 
veneuze bloedglucosewaarden kwamen goed overeen, waarbij de veneuze waarden 
systematisch iets hoger waren. Voor beide capillaire metingen was de opkomst hoog: 
ongeveer 90%. Met een positief voorspellende waarde van 81% (101 van de 125 
patiënten met te hoge capillaire waarden hadden een veneuze bloedglucose van 7,0 
mmol/l of hoger, overeenkomend met diabetes) bleek het protocol goed bruikbaar 
voor het opsporen van onontdekte diabetes.
In Hoofdstuk 4 is de effectiviteit van Diabscreen vastgesteld op basis van het aantal 
gevonden nieuwe mensen met diabetes. Hiervoor werd als controlegroep een 
steekproef van laagrisicopatiënten uitgenodigd voor de bloedglucosemetingen.
 Uiteindelijk had in de hoogrisicogroep 2,7% diabetes type 2 en in de laagrisico-
groep slechts 0,4%. Om één nieuwe patiënt met diabetes te vinden, moesten slechts 
37 hoogrisicopatiënten worden uitgenodigd voor screening, tegen 233 laagrisico-
patiënten (number needed to screen 37 respectievelijk 233). Mensen met obesitas 
(BMI >27) hadden een drie keer grotere kans op het hebben van onontdekte diabetes 
type 2 dan mensen met een normaal gewicht (odds ratio 3,2), waarmee obesitas de 
beste voorspeller voor onontdekte diabetes type 2 bleek te zijn.
 Opportunistische screening op basis van het risicoprofiel in het H-EPD bij 
45-plussers is effectief bij hoogrisicopatiënten, vooral met overgewicht of obesitas, 
maar niet zinvol zonder aanvullende risicofactoren.
Hoofdstuk 5 bevat een commentaar op een recente studie die de kosteneffectiviteit 
van screening naar diabetes type 2 met theoretische modellen had berekend. 
De studie adviseerde opportunistisch te screenen in hoogrisicogroepen. 
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 De resultaten van Diabscreen onderschrijven dit model en laten zien dat 
 opportunistische screening in de huisartsenpraktijk goed uitvoerbaar is en dat dit 
effectief is onder 45-jarige en oudere hoogrisicopatiënten, zeker als ze obesitas 
hebben. 
Hoofdstuk 6 richt zich op de partner van de patiënt met nieuw ontdekte diabetes. De 
partner heeft invloed op het omgaan met de ziekte door de patiënt en uiteindelijk 
ook op ziekte-uitkomsten. Onderzocht werd of de ziektepercepties (illness perceptions) 
van zowel patiënt als zijn/haar partner anders zijn na een diagnose door screening 
dan na een diagnose op basis van diabetesklachten. 
 Patiënten van 40 tot 75 jaar oud met maximaal 3 jaar bekende diabetes werd, 
net als hun partner, gevraagd een korte vragenlijst over ziektepercepties in te 
vullen (de Nederlandstalige versie van de Brief Illness Perception Questionnaire, IPQ-K(ort); 
www.uib.no/ipq of www.ziekteperceptie.nl). Medische gegevens werden bij hun 
huisarts opgevraagd.
 Vooral bij partners had de manier van opsporen van diabetes type 2 – via 
screening of naar aanleiding van klachten – invloed op de ziektepercepties. Partners 
van patiënten met diabetes ontdekt door screening hadden sterker het gevoel dat 
de diabetes invloed had op hun eigen leven, hadden vaker de opvatting dat hun 
partner met diabetes de ziekte goed onder controle had terwijl de patiënt dat zelf 
niet altijd vond, waren meer bezorgd over de diabetes van hun partner, en dachten 
meer dat hun partner klachten had van de diabetes, dan partners van patiënten 
met diabetes ontdekt door klachten.
 Professionals in de diabeteszorg zouden zich meer bewust moeten zijn van 
deze verschillen. Ze zijn eenvoudig vast te stellen door gebruik te maken van een 
vragenlijst zoals de IPQ-K.
In Hoofdstuk 7 wordt een vervolgstudie op Diabscreen beschreven, met gegevens tot 
gemiddeld ruim zeven jaar later. Er is onderzocht of de diagnose diabetes type 2 
door gerichte, opportunistische screening onder hoogrisicopatiënten tot minder 
vaatcomplicaties heeft geleid dan na een diagnose diabetes type 2 bij patiënten 
met diabetesklachten.
 Patiënten opgespoord bij screening bleken bij diagnose vaker al een hart- of 
vaatziekte te hebben dan patiënten uit de klachtengroep, vooral ischemische 
hartziekten (12,3% respectievelijk 3,9%). Maar desondanks was na gemiddeld 7,7 
jaar het percentage opgetreden macrovasculaire complicaties (met name sterfte 
door een hart- of vaatziekte, niet-fataal hartinfarct of niet-fataal herseninfarct) 
in beide groepen gelijk (9,5% respectievelijk 10,2%). Ook het percentage nieuwe 
 microvasculaire complicaties was vergelijkbaar.
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 Opportunistische screening naar diabetes type 2 onder hoogrisicogroepen 
gevolgd door cardiovasculair risicomanagement lijkt de vasculaire uitkomsten 
van diabetes type 2 na bijna acht jaar te hebben verbeterd, maar een duidelijk 
effect is mogelijk pas zichtbaar na een nog langer vervolg.
Hoofdstuk 8 vermeldt de reactie op een ingezonden commentaar op het vervol-
gonderzoek op Diabscreen.
 De auteurs van het commentaar hadden recent gerapporteerd over een eigen 
onderzoek over dit onderwerp. In een gerandomiseerde, gecontroleerde trial (RCT) 
was het percentage sterfgevallen na populatiescreening naar diabetes type 2 
vergeleken met dat percentage na een diagnose op basis van klachten. Na tien jaar 
was er tussen de twee groepen geen significant verschil in totale sterfte of sterfte 
door hart- en vaatziekten. De auteurs menen dat een RCT de beste onderzoeks-
methode is voor deze vergelijking, maar erkennen dat, zolang de kosteneffectivit-
eit van screening naar en vroege behandeling van diabetes nog onzeker is, het 
waarschijnlijk nog het meest efficiënt is om opportunistisch op diabetes te 
screenen onder hoogrisicogroepen op basis van al bekende risicofactoren.
 Hoewel het vervolg op Diabscreen geen RCT was maar een pragmatische, 
observationele studie, zijn de langetermijnuitkomsten wel vergelijkbaar met de 
genoemde RCT en laten ze zien dat op basis van het cardiovasculaire risicoprofiel 
zoals bekend bij de huisarts, hoogrisicogroepen tijdens een toevallig spreekuur-
bezoek kunnen worden opgespoord en/of als onderdeel van cardiovasculair risico-
management kunnen worden gescreend op onontdekte diabetes type 2.
Ten slotte worden in Hoofdstuk 9 de belangrijkste bevindingen van dit proefschrift 
besproken. De belangrijkste methodologische beperkingen komen aan bod, en de 
voor- en tegenargumenten van diabetesscreening worden bediscussieerd. Na 
enkele aanbevelingen voor de dagelijkse praktijk en voor nieuw onderzoek eindigt 
het hoofdstuk met een opsomming van de vijf kernboodschappen van dit proefschrift:
1. Opportunistische screening naar onontdekte diabetes type 2 is goed uitvoerbaar 
in de huisartsenpraktijk, waarbij het elektronisch patiënten dossier goed 
bruikbaar is voor het identificeren van hoogrisicogroepen, mits risicoprofielen 
worden bijgehouden en aangevuld.
2. Diabetesscreening behoort systematisch te zijn geïntegreerd binnen het 
 cardiovasculair risicomanagement, terwijl opportunistische screening naar 
diabetes type 2 het meest effectief is bij 45-plussers met overgewicht of 
obesitas. 
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3. Professionals in de diabeteszorg zouden vaker moeten letten op de ziekte-
percepties van partners van patiënten met diabetes, zeker bij diabetes ontdekt 
door screening. Ziektepercepties zijn eenvoudig vast te stellen door gebruik te 
maken van een korte vragenlijst zoals de IPQ-K.
4. Opportunistische screening naar diabetes type 2 onder hoogrisicogroepen 
gevolgd door cardiovasculair risicomanagement lijkt de vasculaire uitkomsten 
op langere termijn te verbeteren, wat een belangrijk argument is voor screening.
5. Nieuwe studies zouden langetermijnuitkomsten van cardiovasculair risico-
management met geïntegreerde diabetesscreening moeten onderzoeken.
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Begin 2003 – ik zat in het eerste jaar van mijn huisartsopleiding –  kreeg ik een 
e-mail van Wim de Grauw, huisarts en onderzoeker van de (toen nog) afdeling 
Huisartsgeneeskunde van het UMC St Radboud Nijmegen. Ik kende hem nog van 
mijn wetenschappelijke stage in 2000. Zowel de goede sfeer op de afdeling als het 
doen van onderzoek waren goed bevallen en smaakten naar meer. Bij een lopend 
project was nu een vacature ontstaan voor de onderzoeker en Wim vroeg of ik 
geïnteresseerd was. Na een gesprek met hem en projectleider Eloy van de Lisdonk, 
besloot ik de uitdaging aan te gaan. Het werd een zogenaamd aiotho-traject (arts 
in opleiding tot huisarts en onderzoeker), waarbij ik de rest van mijn huisarts-
opleiding zou combineren met promotieonderzoek. Het onderzoek zou na de 
opleiding worden afgerond en de verwachting was dat ik in januari 2006 klaar zou 
zijn. Hoe anders is het gelopen… 
Het onderzoek was lastiger dan gedacht en de financiering bleek eindig. Er ging 
veel (vrije) tijd zitten in het vinden van een eigen lijn in het onderzoek en in het in 
goede tijdschriften gepubliceerd krijgen van de artikelen. Hierdoor maar ook door 
de nodige life events (mijn echtgenote ontmoet, verhuisd en gaan samenwonen, 
huisarts geworden, verloofd, eigen praktijk, getrouwd, weer verhuisd, twee kinderen 
gekregen) werd het al snel 2013. Maar nu kan ik eindelijk zeggen: het ‘boekje’ is af! 
Nou ja, alleen het dankwoord dan nog. Hiervoor kan ik dan wel terugkijken op 
tien bijzondere en boeiende jaren.
Ik had dit project niet kunnen uitvoeren en vooral niet kunnen afronden zonder 
de hulp en steun van velen. 
Allereerst veel dank aan alle patiënten, hun partners, huisartsen en praktijk-
assistentes die hebben deelgenomen aan het in dit proefschrift beschreven onderzoek. 
Zonder hen had ik überhaupt geen artikelen en proefschrift kunnen schrijven.
Tien jaar is een lange tijd, waarin ik vele collega’s van de afdeling Huisartsge-
neeskunde en later Eerstelijnsgeneeskunde heb zien vertrekken en nieuwe heb 
zien komen. Sommige heb ik zelfs nooit gezien of alleen bij afdelingsactiviteiten, 
bruiloften of promotiefeesten, omdat ik de laatste jaren alleen op woensdag 
in Nijmegen kon zijn. Veel dank aan iedereen die mij ooit heeft geholpen of 
belangstelling heeft getoond, of gewoon voor je gezelligheid.
Bijzondere herinneringen heb ik aan de eerste groep aiotho’s: we waren een hechte 
groep en druk met het opstellen van visiedocumenten en inwerkprogramma’s. De 
aiotho-refereeravonden waren nuttig en de uitjes gezellig, en andersom… Allemaal 
veel dank en succes met jullie verdere carrière. Ook de nieuwe generatie aiotho’s 
en de ‘gewone’ promovendi bedankt, en veel succes verder!   
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Ik bedank verder familie, schoonfamilie, vrienden, kennissen, opleiders, collega-
huisartsen, POH-ers, praktijkassistentes, HAP-assistentes en  HAP- chauffeurs, collega- 
bestuurders, managers, medisch specialisten, collega-onderzoekers van buiten 
Nijmegen en alle anderen voor jullie interesse en steun.
Een aantal mensen wil ik graag persoonlijk bedanken.
Chris van Weel, beste Chris, jouw handtekening staat sinds mijn doctoraalexamen 
in 1997 op al mijn diploma’s. Ik vind het een hele eer dat ik nu ook één van je 
(laatste) promovendi ben. En waar je ook was, aan de andere kant van de wereld 
voor een congres of vergadering, of aan het werk in je kamer vlak naast die van mij 
met klassieke muziek op de achtergrond, meestal was jij de eerste van wie ik een 
reactie terugkreeg. Bedankt voor al je steun, je kritische vragen en voor je 
waardevolle commentaren, waarbij je vanuit je brede ervaring mij telkens weer 
wist te stimuleren om onderzoeksresultaten vanuit een breder huisartsgeneeskun-
dig perspectief te bekijken.
Job Metsemakers, beste Job, op afstand vanuit het Maastrichtse hield je de boel in 
de gaten. Gelukkig hebben we tegenwoordig e-mail! Soms hoorde je een tijd niks, 
dan kreeg je ineens weer een nieuw conceptartikel ter beoordeling. Ook jouw 
commentaren waren altijd waardevol. De titel en insteek van hoofdstuk 6 zijn 
grotendeels op jouw naam toe te schrijven. Veel dank voor je betrokkenheid bij 
mijn promotietraject.  
Wim de Grauw, beste Wim, grotendeels dankzij jou kon ik met dit promotieonder-
zoek beginnen en kon ik het ook afmaken. Samen hebben we vele obstakels 
overwonnen en hoogtepunten beleefd. Hoewel we elkaar relatief weinig zagen, 
kon je de laatste tijd dankzij je nieuwe iPhone zelfs vanaf het strand commentaar 
geven op conceptartikelen. Uit eigen ervaring weet ik nu dat de combinatie 
huisarts en onderzoeker heel waardevol is maar ook erg lastig kan zijn, en ik 
heb er in toenemende mate respect voor gekregen hoe jij je staande houdt in de 
onderzoeks- en diabeteswereld en tegelijkertijd een praktiserende Brabantse 
dorpsdokter bent gebleven. Ik bewonder je liefde voor je hond(en) en vind het 
knap dat je nog tijd weet te vinden voor je daarmee samenhangende bijzondere 
hobby. Ik hou je aan je aanbod om samen met Mary en Iti-Marije nog ‘ns uit eten 
te gaan… 
Eloy van de Lisdonk, beste Eloy, jij bent betrokken geweest bij de start van 
Diabscreen, waarmee je aan de wieg hebt gestaan van mijn promotieonderzoek. 
Heel veel dank voor je betrokkenheid en commentaren in de beginjaren, en voor 
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je interesse die is gebleven ook nog na je pensioen. Het is wel een stuk stiller op de 
woensdagen nu je aanstekelijke lach niet meer over de gang klinkt…
Henk van den Hoogen, beste Henk, jij bent al weer wat langer met pensioen, maar 
ik ben blij dat ik je de eerste jaren nog heb meegemaakt. Als statisticus en 
IVES-hoofd kon ik altijd bij je terecht met lastige statistische en methodologische 
vragen, waarbij je stimuleerde om het gezonde verstand te gebruiken en om na te 
denken over de betekenis van uitkomsten. Veel dank daarvoor.
Willem van Gerwen, beste Willem, wij hebben vooral in het begin van mijn promotie-
onderzoek intensief samengewerkt. Jij beheerde de toen in mijn ogen ongelofelijk 
ingewikkelde SAS-databestanden. Het bleek inderdaad ook niet eenvoudig om de 
juiste gegevens eruit te krijgen, maar het lukte je uiteindelijk toch. Het vloeken dat 
er regelmatig voor nodig was heb ik niet gehoord… Heel veel dank voor al je werk 
en voor het mij leren lezen en begrijpen van tabellen met bijbehorende statistische 
analyses. Ik ben blij dat je één van mijn paranimfen bent. 
Reinier Akkermans, beste Reinier, als co-auteur van een van mijn artikelen maar 
ook als vraagbaak voor statistische en methodologische vragen over andere 
artikelen kon ik de laatste jaren altijd bij je aankloppen. Heel veel dank daarvoor. 
Ik ben blij dat je ook mijn paranimf bent. Veel succes met het afronden van jouw 
promotie! 
Marion Biermans, beste Marion, heel veel dank voor je co-auteurschap van het 
artikel over ziektepercepties. Als epidemioloog en teamleider van de expertisegroep 
MIMS (het voormalige IVES) van de afdeling Eerstelijnsgeneeskunde, waren je 
adviezen en betrokkenheid zeer welkom.
Ook van de volgende medewerkers van MIMS heb ik regelmatig hulp of advies 
gekregen, waarvoor veel dank: Hans Bor, Jan Mulder en Waling Tiersma.
Mieke Cardol, beste Mieke, ook jij bedankt voor je co-auteurschap van het artikel 
over ziektepercepties. Dankzij jouw voorwerk kon ik dit artikel zo schrijven, dat 
het paste binnen mijn promotieonderwerp.
Susanne van Keeken, beste Susanne, dank voor je werk in het kader van je weten-
schappelijke stage. Jouw verslag diende als basis voor het vervolgartikel van 
Diabscreen, waarvan je dan ook co-auteur bent geworden.
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Wetenschappelijk onderzoek kan niet worden uitgevoerd zonder onderzoeksassis-
tentes. Ik heb vooral te maken gehad met Nicol Orbon, veel dank voor je werk voor 
Diabscreen, Nicol. Ik wil hierbij zeker ook Linelle Deunk bedanken, tegenwoordig 
een beroemd fotografe, maar vóór mijn tijd betrokken bij de regelzaken van 
Diabscreen.
Heert Tigchelaar, beste Heert, als mijn voorganger ben je betrokken geweest bij de 
opzet en uitvoering van Diabscreen, waarvoor veel dank.   
Ben Bottema, beste Ben, als hoofd van de huisartsopleiding heb je mijn aiotho-schap 
mogelijk gemaakt. Ook heb je mij en ook andere aiotho’s bijgestaan toen er in de 
eerste jaren van het aiotho-schap regelmatig onduidelijkheden waren en zelfs 
conflicten ontstonden met onze formele werkgever SBOH, zoals die keer dat ik me 
daar moest melden omdat ik volgens de SBOH geen onderzoek had mogen doen in 
hun tijd. Veel dank voor je steun.
Een secretariaat is van levensbelang, ook voor de afdeling Eerstelijnsgeneeskunde. 
Twanny Jeijsman, beste Twanny, inmiddels stafmedewerker, veel dank voor alles 
wat je voor me hebt geregeld, waaronder de eerste opzet van dit boekje. Jammer 
dat je niet op woensdagen werkt, maar gelukkig sprak ik je nog wel bij bruiloften 
en promotiefeesten. Nu is het dan eindelijk mijn beurt! Ook dank voor jullie hulp 
en belangstelling: Caroline Roos, Dorothé Jackson, Marike Jaegers.
De woensdag was de laatste jaren mijn onderzoeksdag. De rustigste dag van de 
week, maar gelukkig waren er altijd mensen om samen mee te lunchen, die 
belangstelling hadden en voor gezelligheid zorgden. Een paar mensen wil ik hier 
in het bijzonder noemen: Margriet Straver, lieve Margriet, dank voor je verhalen, 
voor je interesse en voor je luisterend oor. Sinds jouw pensioen is de woensdag niet 
meer wat die is geweest.
Harry Wagenvoort, beste Harry, ook jij was jaren een trouwe ‘lunchganger’ op de 
woensdag. Dank voor je gezelschap, en gelukkig dat je voorlopig weer werk hebt op 
de afdeling.
Toine Lagro-Janssen, beste Toine, ondanks al je bezigheden was je toch altijd 
geïnteresseerd in mijn onderzoek, in mijzelf en in mijn gezin. Heel veel dank daarvoor. 
Sietske Grol, beste Sietske, met een korte onderbreking sinds enkele jaren kamer - 
genoot op de woensdag, dank voor je gezelschap, je antihoestsnoepjes en al je 
bouwadviezen.
Hierbij ook speciale dank aan mijn vroegere kamergenoten Jeroen van Adrichem 
en Caroline van Wayenburg, en aan kamergenoot Floris van de Laar die af en toe 
nog aan het werk was op woensdag.
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Zoals ik hierboven al heb vermeld, is de combinatie huisarts en onderzoeker niet 
makkelijk, zeker de laatste jaren waarin ik in mijn vrije tijd aan het onderzoek 
moest werken. Dit was niet mogelijk geweest zonder mijn part-time werk in mijn 
eigen huisartsenpraktijk in Ede, die ik, na een jaar in loondienst te zijn geweest, 
sinds 2008 samen heb met mijn collega en maat Inge Meekes. Inge, bedankt dat je 
me na die ene gezamenlijke nachtdienst hebt benaderd om mee te solliciteren toen 
je collega met pensioen ging. Bedankt voor de prettige samenwerking in onze 
maatschap. Ook veel dank aan praktijkassistentes Bettina, Melissa, Irene en Linda, 
oud-praktijkassistente Rosanne en praktijkondersteuners Nely en Tia voor jullie 
werk, gezelligheid en (meestal…) begrip. Ook bedank ik al onze huisartsen in 
opleiding die de afgelopen jaren bij ons hebben gewerkt.
Nic Magis, beste Nic, we kennen elkaar al sinds het begin van onze studie en niet 
veel mannen kunnen zeggen dat ze met elkaar in een klein tentje in Schotland 
hebben geslapen. Nu ik het rustiger krijg moeten we, ondanks de afstand, maar 
weer ‘ns afspreken.
Barend Heeren en Twan Willems, beste Barend en Twan, bedankt voor onze regel- 
matige Baert-ploegenmaaltijden, een welkom rustpuntje in een drukke werkweek, 
gewoon simpel met een biertje, al weer sinds 1998.
Mijn broer Maurice en schoonzus Chantal, bedankt voor jullie interesse. Geniet 
van jullie (toekomstige) gezin.
Lieve schoonouders, lieve Koos en Adri Smits, door jullie steun aan en betrokkenheid 
bij ons gezin, ondanks jullie eigen moeilijke situatie, is dit proefschrift ook deels 
jullie verdienste. Heel veel dank daarvoor.
Lieve ouders, lieve mam en pap, veel van wat ik heb bereikt heb ik aan jullie te 
danken. Jullie stimuleerden me al vroeg om te gaan studeren door mee te gaan 
naar de open dagen van de universiteit. En jullie ondersteunden en hielpen me 
waar nodig toen ik daadwerkelijk ging studeren en op kamers ging. Dat ik dit 
proefschrift heb kunnen afmaken is grotendeels te danken aan de door jullie 
gelegde basis. Bedankt dat jullie altijd voor mij klaar hebben gestaan, en nu klaar 
staan voor ons gezin.  
Lieve Sander en Jasper, wat ben ik blij dat jullie in ons leven zijn gekomen! Als 
jullie dit later lezen zijn jullie het vast alweer vergeten, maar thuis rustig werken 
aan mijn proefschrift zat er nauwelijks in als jullie in de buurt waren. Jullie 
wilden altijd typen of filmpjes kijken van graafmachines of brandweerauto’s, net 
158
Dankwoord
als papa moest werken achter de computer. Gelukkig maakten jullie lieve lach en 
vele knuffels het allemaal weer goed. Ik ben blij dat we nu weer meer samen kunnen 
gaan doen!
Lieve Iti-Marije, partners matter! Partners zijn belangrijk! Ik ben dan wel aan mijn 
promotietraject begonnen voordat ik je kende, maar afronden was niet gelukt 
zonder jouw steun en toeverlaat. Dankzij jou kon ik op mijn vrije woensdag naar 
Nijmegen om daar te werken aan mijn proefschrift, terwijl jij ons gezin onder je 
hoede nam. En dat deed je ook al die weekenden en vakantiedagen waarop ik thuis 
moest werken. Daarnaast ging je ook nog door met de verzorging van je vader. Niet 
voor niets heb ik ‘ons’ beeld in het prachtige Italiaanse Cinque Terre opgenomen 
op de omslag van dit proefschrift. Heel veel dank voor alles. Ik kijk ernaar uit meer 
tijd met jou en ons gezin te kunnen doorbrengen!
Erwin Klein Woolthuis
mei 2013
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About the author
Erwin Klein Woolthuis was born on November 12, 1974 in Deventer, a city in the 
eastern part of the Netherlands. He grew up there as well. In 1993 he completed his 
high school at the Alexander Hegius Public School (nowadays Etty Hillesum 
Lyceum) in Deventer and was admitted to study medicine at the Radboud University 
Nijmegen. After two years he joined the Nijmegen Student Rowing Club Phocas, of 
which he was a full-time board member from 1997 to 1998. On December 22, 2000 
he passed his medical finals.
He then worked as a resident at the Bernhoven hospital in Veghel until the start of 
his GP vocational training at the Radboud University Nijmegen Medical Centre in 
March 2002.
In September 2003 he started combining vocational training with research training 
and became one of the first GP medical research trainees (aiotho in Dutch) at the 
Department of Primary and Community Care of the Radboud University Nijmegen 
Medical Centre. 
In 2005 he completed his vocational training, after which he worked as a GP in 
several general practices and out-of-hours GP clinics, while continuing his research. 
The results of that research are described in this doctoral (PhD) thesis.
Since 2007 he has been working together with GP Inge Meekes in their joint general 
practice in Ede, a city in the center of the Netherlands. The practice participates in 
education, in particular the GP vocational training, and in research programmes 
of the Radboud University Nijmegen Medical Centre.  
The author is a member of the Dutch GP expert group on diabetes (DiHAG) and of 
the European Association for the Study of Diabetes (EASD), and is working as a 
diabetes expert in primary care in the Gelderse Vallei region.
He is also a board member of the District of Groot Gelre of the Royal Dutch Medical 
Association (KNMG) and of the Gelderse Vallei cooperative union of GPs.
Erwin Klein Woolthuis is married to Iti-Marije Klein Woolthuis-Smits. Together 
they have two sons: Sander and Jasper.
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Erwin Klein Woolthuis werd geboren op 12 november 1974 in Deventer. Daar 
groeide hij ook op. Hij behaalde in 1993 zijn gymnasiumdiploma aan de Openbare 
Scholengemeenschap Alexander Hegius (tegenwoordig Etty Hillesum Lyceum) in 
Deventer. Dankzij een gunstige loting kon hij aansluitend geneeskunde gaan 
studeren aan de Radboud Universiteit Nijmegen (toen nog Katholieke Universiteit 
Nijmegen). Na twee jaar werd hij lid van de Nijmeegse Studenten Roeivereniging 
Phocas, waarvan hij van 1997 tot 1998 met een universitaire beurs een jaar full-time 
bestuurslid was. Op 22 december 2000 is hij geslaagd voor zijn artsexamen.
Daarna werkte hij als arts-assistent in ziekenhuis Bernhoven in Veghel tot de start 
van zijn huisartsopleiding aan het Universitair Medisch Centrum St Radboud 
Nijmegen in maart 2002.
In september 2003 kreeg hij de mogelijkheid om de huisartsopleiding te combineren 
met promotieonderzoek als één van de eerste aiotho’s (arts in opleiding tot huisarts 
en onderzoeker) bij de afdeling Huisartsgeneeskunde (nu Eerstelijnsgeneeskunde) 
van het Universitair Medisch Centrum St Radboud. 
In 2005 werd hij huisarts, waarna hij als waarnemend huisarts heeft gewerkt in 
diverse huisartsenpraktijken en huisartsenposten. Daarnaast deed hij het promotie - 
onderzoek, waarvan de resultaten in dit proefschrift zijn beschreven. 
Sinds 2007 werkt hij samen met huisarts Inge Meekes in hun gezamenlijke huis-
artsenpraktijk in Ede. Deze praktijk biedt als Nijmeegse Universitaire Huisarts-
praktijk stageplaatsen voor de opleiding geneeskunde en de huisartsopleiding 
van het Universitair Medisch Centrum St Radboud. Daarnaast neemt de praktijk 
regelmatig deel aan wetenschappelijk onderzoek. 
De auteur is lid van de Diabetes Huisartsen Advies Groep (DiHAG) en de European 
Association for the Study of Diabetes (EASD), en is werkzaam als kaderhuisarts 
diabetes voor de zorggroep Gelderse Vallei.
Hij is tevens bestuurslid van district Groot Gelre van de Koninklijke Nederlandsche 
Maatschappij tot bevordering der Geneeskunst (KNMG) en van de coöperatieve 
vereniging Huisartsen de Gelderse Vallei. 
Erwin Klein Woolthuis is getrouwd met Iti-Marije Klein Woolthuis-Smits. Samen 
hebben ze twee zonen: Sander en Jasper.  
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